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ABSTRACT 
 
Breast cancer is a disease that will be diagnosed in about 1 in 10 women 
throughout their lifetime. The majority of breast cancers are originated from the 
epithelial cells of the mammary ducts, and this occurrence can be due to several factors 
including hereditary and acquired mutation. There are several major breast cancer 
subtypes, including estrogen receptor-α (ERα)-positive, HER2-enriched and triple-
negative (TNBC). Patients diagnosed with ER+ tumors are generally treated with 
estrogen blockers (e.g., tamoxifen, letrozole and fulvestrant). Patients with HER2+ 
tumors are commonly administered with drugs that block HER2 signaling (e.g., 
trastuzumab) or inhibit HER2’s tyrosine kinase activity (e.g., lapatinib). For patients with 
TNBC, chemotherapies such as taxanes and anthracyclines are standard of care 
therapies. 
 However, for each breast cancer subtype, a significant number of patients 
develop resistance to these therapies and eventually die from metastasis, a process 
which accounts for ~90% of breast cancer mortality. Currently, metastatic breast cancer 
is incurable, and the short median survival of 3 years for patients with metastatic breast 
cancer has not significantly changed in over 20 years. Therefore identification of new 
molecules that are involved in breast cancer metastasis and development of more 
  
x 
precisely targeted therapeutic strategies are urgently needed to improve the clinical 
outcome for this disease. 
The transforming growth factor pathway beta (TGFβ) pathway has been show to 
play a key role in metastasis through induction of epithelial-mesenchymal transition 
(EMT), cell migration and invasion.  Over more than a decade, this pathway has been 
studied across several cancers and it is now better established that it has context-
dependent tumor suppressive and oncogenic qualities. In the early stages of breast 
cancer, TGFβ pathway is a suppressor of benign and early stage tumor growth. 
However, as disease progresses and corresponding levels of TGFβ ligands become 
elevated, a “switch” will take place and promote oncogenic phenotypes like EMT and 
cancer cell stemness which drive metastasis. 
 Long noncoding RNAs (lncRNAs) are an emerging subclass of RNA molecules in 
cancer biology. LncRNAs are >200nt and can influence target gene expression locally in 
“cis”, or along a distant chromosome in “trans”, through various mechanisms and 
interactions with other biological molecules. The contribution of TGFβ-regulated 
lncRNAs to associated phenotypes like EMT and cancer cell stemness has not been 
very well studied. The aim of this doctoral dissertation is to address the functional and 
mechanistic roles of lncRNAs in these processes.  Using a well-established TGFβ-
induced EMT model (e.g., mouse mammary epithelial cell NMuMG treated with TGFβ), 
we have identified 3 conserved lncRNAs (lncRNA-HIT, WDFY3-AS2 and TIL) that are 
significantly upregulated upon TGFβ-induced EMT. They all mediate TGFβ-induced 
EMT, cell migration and invasion.  Overexpression of these lncRNAs is frequently 
detected during the breast cancer progression and is associated with high grade and 
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late stage of breast cancer as well as metastatic lesion.  We have also demonstrated 
that lncRNA-HIT positively regulates HOXA13 through “cis” mechanism and that 
WDFY3-AS2 induces WDFY3 and STAT3 expression at mRNA level by direct 
interaction with hnRNP-R.  Interestingly, TIL stimulates C-MYC protein but not mRNA 
expression by promoting Akt phosphorylation of NF90 leading to its translation from the 
nucleus to cytosol where NF90 binds to C-MYC mRNA and enhances C-MYC 
translation.  Importantly, we have shown that knockdown of lncRNA-HIT and WDFY3-
AS2 significantly reduces breast cancer growth and lung metastasis in orthotopic breast 
cancer model.  These findings indicate that these TGFβ-induced lncRNAs play critical 
role in EMT, metastasis, and are relevant in human patient tumors. Therefore, it is 
important to consider utilizing these molecules for clinical applications like diagnosis, 
monitoring recurrence, predicting a response to therapy, and even as a direct target for 
therapeutic intervention. 
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CHAPTER 1 
Background 
 
Breast Cancer. In 2014, there will be an estimated 230,000 new cases of breast 
cancer diagnoses and 40,000 deaths resulting from the disease [1]. Breast cancer can 
arise in various anatomic locations within the breast. Commonly, cancer will arise in the 
ducts towards to front of the breast, and less frequently in the lobules that locate closer 
to the chest wall and the other areas in between. Upon diagnosis breast cancer staging 
will occur, which accounts for size of primary mass, degree of invasiveness, and 
presence of metastasis in lymph nodes or other parts of the body. Patients diagnosed in 
early stages (e.g., stage I or stage II) and who present no local dissemination of cells in 
lymph node have a very good prognosis with 5-year survival greater than 90%. 
However, if diagnosed at later stages, 5-year survival drops significantly to 72% at stage 
III and 22% presenting at stage IV. For this reason, early diagnosis and prevention are 
critical for improving patient survival. 
Several factors have been linked to increasing an individuals risk for developing 
breast cancer throughout their lifetime including genetic predisposition, atypical 
menstruation patterns, obesity, high fat diet, and lacking exercise. There is no way to 
predict who will develop breast cancer, however it is important to be aware of familial 
history, have regular mammogram screening, and maintain healthy lifestyle to best 
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prevent disease occurrence. There are 3 standard therapies used to treat breast cancer, 
surgery, radiation, and chemotherapy [2]. For most early stage cancers, surgical 
lumpectomy is sufficient treatment which removes a small mass and some normal 
surrounding tissue to clear borders of any residual cancer cells. If the disease is more 
advanced, surgery can become more invasive and favor partial or modified radical 
mastectomy where larger portions or complete breast is removed. External or internal 
radiation treatments (high energy x-rays) are usually given post-surgery to locally clear 
the area of any remaining cancer cells. Several chemotherapeutic drugs are now 
approved for treatment of breast cancer in form of alkylating agents, anthracyclines, 
platinum drugs and taxanes [2]. The chemotherapeutic treatment chosen will also likely 
take into account pathological characteristics of tumor as more targeted therapies 
become available. 
 
Types of Breast Lesions and Carcinomas. Breast cancers originate in the 
epithelial compartment once increased cellular proliferation and abnormal cellular 
architecture becomes evident. There is typical progression from normal to pre-
cancerous lesion to carcinoma that initially presents itself in the form of a hyperplasia. 
The term of hyperplasia refers increased number of proliferative cells, and is 
accompanied by an increase in cell size referred to as hypertrophy. A hyperplasia is  a 
benign lesion, but can develop into a neoplasia or pre-cancerous lesion once genetic 
abnormalities persist and the cell becomes unresponsive to cues that halt cell cycle and 
resist apoptosis. The aggressiveness of the lesion can be evaluated by the tumor grade. 
These features are clinically and pathologically relevant as to how a pre-cancerous 
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lesion is diagnosed and provide information as to rate of recurrence and how 
aggressive the carcinoma may become [3]. 
Ductal carcinoma in situ (DCIS) is the most common form of breast tumor 
associated with development of invasive breast cancer. DCIS is considered stage 0 
breast cancer, as this refers to the fact that the mass has yet to become invasive and 
push past the boundaries of the basement membrane remaining confined to the duct [4]. 
Depending on how the mass is formed and patterned DCIS can be subdivided into 
papillary, with finger-like projections, crib-form in which there are gaps between cells, or 
solid in which gaps are completely filled inside and blocking the duct [5]. Lobular 
carcinoma in situ (LCIS) anatomically presents itself in the lobular compartment of the 
breast. The lobular component of the breast is the milk producing area located beyond 
the ducts and closer to the chest wall. LCIS, like DCIS, is confined to the lobules and 
has not invaded or spread to any surrounding tissues. LCIS is less frequently diagnosed 
however, as it is hard to view via standard mammogram and no symptoms are present 
during this stage of pre-cancerous lesion. 
Invasive ductal carcinoma (IDC) is the most common type of breast cancer 
encompassing about 80% of all diagnoses.  Advanced DCIS will form IDC once the 
mass has spread beyond the boundaries of the basement membrane and has infiltrated 
the surrounding tissue of the breast. Early detection of IDC is critical in that once the 
tumor protrudes through the duct wall metastasis to the lymph node or other parts of the 
body can rapidly occur. The majority of cases of women at diagnosis are post-
menopausal and close above the age of 55. Invasive lobular carcinomas (ILCs) are 
much less commonly diagnosed and account for about 10% of all new breast cancer 
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cases. ILC results once LCIS has spread into the surrounding tissues and areas of the 
breast surrounding the lobules. It is common for women to be diagnosed with ILC at a 
later age than IDC and it has also been suggested that hormone replacement therapy 
can trigger development of this disease. 
 
Hereditary Breast Cancer. Hereditary breast cancer refers to inherited 
mutations in particular genes that put women at higher risk for developing breast cancer 
throughout their lifetime and at an earlier age. The most common type of hereditary 
breast cancer is inheriting mutations in a single copy of either BRCA1 or BRCA2 genes 
[6]. The mutations in BRCA1 and BRCA2 are referred to as single nucleotide 
polymorphisms (SNPs), which are naturally occurring variations within the DNA of the 
genome that differs by one nucleotide within a population. SNPs that locate within the 
coding region or open reading frame of a protein have the ability to alter amino acid 
sequence and protein secondary structure which can alter normal gene function and 
protein stability. BRCA1 and BRCA2 are referred to as tumor suppressor genes, 
responsible for DNA damage repair and maintaining chromosomal stability and integrity 
[7]. Patients who inherit a mutation within one of these two genes will have deficient 
DNA damage repair response and accumulate genetic mutations at a higher rate than 
those with normal BRCA status. These associated mutations account for the majority of 
hereditary breast cancer, and about 10% of all new case of diagnosed breast cancers. 
There are several other genes that have also been implicated in familial and 
hereditary breast cancer, however no other gene mutations have showed comparable 
penetrance rate as that of BRCA1 and BRCA2. Many of the other genes that have 
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shown susceptibility to breast cancer development are also involved in the DNA 
damage repair pathway, which include ATM, CHEK2, PALB, RAD50, and MRE11 [8-12]. 
 These genes all play critical roles in DNA damage repair, and can form complex 
with each other to elicit a robust functional response. Therefore, it is possible that a 
mutation rendering one of these genes non-functional can result in faulty repair due to 
dominant-negative effect. Other classical tumor suppressor genes have also been 
implicated as contributing to hereditary breast cancer, including p53 and PTEN genes 
[13, 14]. P53 is the most commonly mutated gene in all of human cancer (~50%), and is 
critical for cell cycle arrest and initiation of apoptosis. PTEN tumor suppressor is the 
major negative regulator of PI3K/AKT signaling pathway. Loss of PTEN expression and 
function can occur through various mechanisms, resulting in increased cell survival and 
proliferation. 
 
Molecular Pathological Subtypes of Breast Cancer. Luminal A and luminal B 
are the most common types of breast cancer accounting for 40% and 20% of all 
diagnosed cases, respectively [15]. Luminal breast cancers are named such in that they 
originate from the epithelial layer of the luminal lining in the mammary duct. Luminal A 
breast cancer is defined molecularly as estrogen receptor-positive (ER+) and/or 
progesterone receptor PR-positive (PR+), HER2/neu receptor-negative (HER2-), and a 
low percentage of p53 mutation (<15%). Luminal A has the most positive prognosis of 
all subtypes of the breast cancers, a low recurrence rate, and targeted hormone 
therapies based on ER-positive status [16, 17]. 
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Luminal B cancers are classified same as luminal A in ER+ and/or PR+, however 
are also HER2+ and have a greater Ki-67 index which is a marker of cellular 
proliferation. The prognosis for luminal B tumors is poorer than those diagnosed for 
luminal A. Several factors such as up-regulation of the HER2 receptor, frequent p53 
mutations, poorly differentiated tumor, and larger tumor size all contribute to poorer 
survival rates. Although, given ER+ and HER2+ status, targeted and hormonal 
therapies do exist for luminal B cancers [18]. 
HER2/neu subtype refers to a breast cancer in which this is the only the HER2 
receptor up-regulated, and not ER or PR. HER2/neu subtype accounts for the least 
amount of cases diagnosed amongst all the subtypes at only about 10-15% of all cases. 
HER2/neu tumors tend to be diagnosed at younger age, have more frequent recurrence, 
higher rates of metastasis, and poorer prognosis primarily due to accompanying large 
percentage of p53 mutations [19]. A monoclonal antibody targeted therapy called 
trastuzumab (Herceptin) is commonly used to treat HER2+ tumors [20]. 
Triple-negative breast cancer (TNBC) subtypes are negative for all three 
receptors (e.g., ER, PR and HER2) and have by far the poorest prognosis of all breast 
cancers. The 5-year survival for early stage diagnosis of triple negative breast cancer is 
only 77% [21]. TNBC is more basal-like as compared to other subtypes having features 
reminiscent of the cells surrounding the mammary duct and not in the lumen. These 
tumors tend to be very aggressive with high rates of metastasis, and due to the negative 
status of all receptors there are limited treatment options outside of surgery, radiation, 
and standard chemotherapy [22]. 
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Recent advances in technology like whole genome sequencing, microarray, RNA 
sequencing, and proteomic analysis have been valuable tools in continually redefining 
the molecular subtypes of breast cancer [23, 24]. Although the technology is still in its 
youth, these approaches, and more importantly, the combination of these approaches 
will likely stratify these established subtypes further or give rise to novel subtypes of 
breast cancer. This is an important area of research as the sorting and understanding of 
all this new information is critical for personalized medicine and the development of new 
targeted therapies. 
 
Human genome and long noncoding RNAs (lncRNAs) 
 
Genomic landscape. The central dogma of molecular biology has defined the 
linear progression of biological identity and function as “DNA makes RNA, makes 
protein.” Translation to protein has traditionally been the requirement for a particular 
DNA sequence to be assigned the title of “gene”. The completion of the Human 
Genome Project significantly expanded our insight into absolute genomic landscape, 
and has allowed for scientists to map and organize ~3 billion base pairs to a more 
precise number of protein-coding genes, often cited as 20,000 to 25,000 [25]. RNA has 
customarily been reduced to the role of an intermediate, conveniently modified and 
processed in a highly regulatory manner, with a sole purpose to relay the appropriate 
language for building a functional protein. It is interesting to note however, that when a 
more global view of the human genome reveals that only ~1.5% accounts for protein 
coding exons, increasing to ~2% if including introns and untranslated regions (UTRs) 
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[26]. The vast majority of the remaining uncharacterized genome aside from 
housekeeping RNAs was thought not to be expressed and coined “junk DNA,” and this 
has served as a suitable designation for some time. 
In recent years, however, modern technologies such as tiling arrays, massive 
parallel sequencing, and RNA-sequencing have demonstrated that the human 
transcriptome is much larger than previously thought, giving rise to a paradigm shift in 
molecular biology known as the “RNA Hypothesis” [27-29]. Current estimates now 
consider that ~70% of the human genome is transcribed into RNA, a discovery that 
provides justification to reconsider what constitutes the functional genome, and place 
greater emphasis on what is defined a “gene” [30]. To date, several classes of non-
coding RNAs (ncRNAs) have been categorized and well-defined, demonstrating the 
diversity and dynamic role of RNA in cellular function (Table 1) [31-33]. A recent 
example of this shift is the extensive study and documentation of microRNAs (miRNAs), 
a class of small RNAs that illustrate the sophistication RNA potentiates in exerting direct 
function in biological processes [34]. The most recent advance has led to the discovery 
and rapid characterization of another novel group of ncRNA, termed long noncoding 
RNA (lncRNA). 
 
Characteristics of lncRNA. The current and general parameters for defining 
lncRNAs are as follows; 1). polyadenylation at 3’ UTR in a majority of lncRNAs, 2). 
epigenetic markers including trimethylation at lysine-4 of H3 (H3K4me3) at the promoter 
and trimethylation at lysine-36 of H3 (H3K36me3) along transcribed region, 3). active 
transcription via RNA polymerase II (RNA pol. II), 4). regulation by established 
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transcription factors, 5). processing via canonical exonic splice sites, 6). >200 bp long 
without open-reading frame and 7). tissue-specific expression (Fig 1A) [35, 36]. There 
 
Table 1. Species of RNA in the human genome. 
 
 
 
are exceptions however, and examples of non-polyadenylated lncRNAs transcribed via 
RNA polymerase III have been reported [37, 38]. The majority of these features emulate 
characteristics of messenger RNAs (mRNAs), emphasizing the notion that lncRNAs are 
under precise transcriptional control and processed in the same manner as functional 
 
Species of RNAs in human genome 
Transfer RNAs (tRNAs) 
Ribosomal RNAs (rRNAs) 
Small nuclear RNAs (snRNAs) 
 
 
Housekeeping RNAs 
Small nucleolar RNAs (snoRNAs) 
Micro RNAs (miRNAs) 
Short interfering RNAs (siRNAs) 
Tiny transcription initiation RNAs 
Repeat associated small interfering RNAs 
Promoter associated RNAs 
Retrotransposon derived RNAs 
Splice site RNAs 
 
 
 
Small RNAs 
(<200nts) 
Anti-sense termini associated RNAs 
Long noncoding RNAs (lncRNAs) 
Pseudogenes 
Transcribed ultra-conserved regions 
Enhancer RNAs (eRNAs) 
 
 
Large RNAs 
(>200nts) 
Repeat associated long ncRNAs 
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protein-coding transcripts. The directionality of lncRNA is usually defined in reference to 
the nearest protein coding gene, and can exhibit orientations in antisense, bidirectional, 
sense, intronic and intergenic (Fig 1B). 
 
 
Figure 1. The characteristic features and orientation of lncRNAs. (A) There are 
several defining features of lncRNAs which distinguishes these transcripts as a class. 
(B) LncRNA orientation is defined in relation to the transcriptional start site (TSS) of the 
nearest protein coding gene. LncRNA can be transcribed antisense, bi-directional, 
sense, intronic, or intergenic orientations. Reproduced from ‘Edward J. Richards and Jin 
Q. Cheng, 2014, Long noncoding RNAs and their expanding roles in cancer, Current 
Topics in Biochemical Research, Vol. 16, 81 – 95’. 
 
Conservation of lncRNA. The conservation of lncRNAs has been the topic of 
extensive debate and study. The significance of linking these attributes to lncRNA would 
provide strong evidence for functionality suggesting these transcripts were retained 
through selective pressures. By and large, however, lncRNAs exhibit poor sequence 
conservation across species in comparison to protein coding genes and microRNAs [39, 
40]. One study reported that in starting with a pool of tissue specific human lncRNAs, 
80% contained an ortholog transcript in chimpanzee, and this decreased to only 39% in 
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mice [41]. Thus, given the fact that the protein coding genome is almost entirely 
conserved across higher organisms, the noncoding genome likely is a key contributor to 
species identity and complexity. From an evolutionary perspective, it has been 
suggested that lncRNAs are rapidly evolving regulatory elements of high plasticity 
responsible for continually mobilizing mammalian evolution [40]. This concept is very 
striking given the short evolutionary distance between humans and chimpanzee, and 
lncRNAs account for about half the genetic differences between the two genomes [42]. 
It is also important to remember that selecting for a protein coding gene and 
lncRNA needs to be considered independent and mutually exclusive processes. 
Conservation of a functional protein coding gene requires high sequence preservation 
to ensure proper amino acid coding and secondary protein folding. Any disruption in 
sequence can drastically alter the biological function of a protein, and likely this 
contributes to the high conservation of proteins across several species. On the contrary, 
lncRNAs do not require significant sequence retention along the entire body of the 
transcript to retain appropriate architecture and secondary structure necessary for 
function. LncRNA function can occur through a protein binding site, a miRNA seed site, 
mRNA recognition sequence, or DNA binding element, all of which require relatively 
short stretches of sequence for utility. A prime example is the X-inactive specific 
transcript  (XIST), a 17-kb transcript in human in which conservation is only retained in 
exon 1, and this conserved region is critical for proper function [43]. Also, despite a lack 
of lncRNA sequence conservation in and of itself, the promoters of lncRNAs 
demonstrate very high sequence conservation and are capable of binding established 
transcription factors [44]. 
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Mechanisms of lncRNA Function 
 
Epigenetic and chromatin modification. LncRNAs can regulate gene 
expression within a few megabases along the same chromosome or from a distance at 
a different chromosome. This regulation is referred to as acting in “cis” and in “trans”, 
respectively (Figure 2). The XIST is a very well studied lncRNA that functions in “cis”. In 
developing mammalian females, X-chromosome inactivation is a critical compensatory 
mechanism to ensure gene dosage equivalency between males and females along the 
X-chromosome. XIST mediates this process through its exclusive expression on the 
inactive X-allele via the X-chromosome inactivation center (Xic) [43, 45]. The first exon 
of XIST contains a double hairpin motif capable of binding polycomb recessive complex 
2 (PRC2), and recruitment of this histone methyltransferase complex results in tri-
methylation of lysine 27 at H3 (H3K27me3) and transcriptional silencing along the 
inactive X-chromosome [46]. Interestingly, the active X-chromosome represses XIST 
expression through interaction with an antisense lncRNA known as TSIX, yet an exact 
mechanism has yet to be determined for this modulation [47]. 
One of the better characterized lncRNAs that functions in epigenetic and 
chromatin modification in “trans” is HOX antisense intergenic ncRNA (HOTAIR). 
HOTAIR is located on chromosome 12 and is oriented antisense to the HoxC cluster, 
and transcriptionally represses the HoxD locus on chromosome 2 [48]. There are two 
functional domains of HOTAIR, a PRC2-binding domain at the 5’ end which interacts 
with subunit Suz12, and an LSD1/CoREST1-binding domain at the 3’ end. It is 
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suspected that these two complexes use HOTAIR as a modular scaffold for 
collaboration and recruitment to target gene locations [49]. The precise mechanisms for 
 
 
 
 
 
Figure 2. LncRNA functions in “cis” or in “trans”. LncRNAs that function locally on 
the chromosome of origin are referred to as functioning in “cis”. This is the case of XIST, 
which is transcribed at X-chromosome inactivation center (XIC) and is responsible for X-
chromosome inactivation. LncRNAs can also regulate target gene expression on distant 
chromosomes in “trans”, such as HOTAIR which is transcribed from HoxC gene cluster 
on chromosome 12, yet represses target HOXD expression on distant chromosome 2. 
Reproduced from ‘Edward J. Richards and Jin Q. Cheng, 2014, Long noncoding RNAs 
and their expanding roles in cancer, Current Topics in Biochemical Research, Vol. 16, 
81 – 95’. 
 
 
how “trans” functioning lncRNAs target specific genes on distant chromosomes are still 
not well understood. There have been several additional mechanisms reported for 
lncRNA function (Table 2). 
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Table 2. The biological mechanisms of lncRNA function. 
 
 
Reproduced from ‘Edward J. Richards and Jin Q. Cheng, 2014, Long noncoding RNAs 
and their expanding roles in cancer, Current Topics in Biochemical Research, Vol. 16, 
81 – 95’. 
 
 
Sponge for miRNAs. It is becoming more apparent that some lncRNAs contain 
multiple miRNA response elements (MREs), which layers ncRNA regulation through 
competition. This theory is known as the competing endogenous RNA (ceRNA) 
 
Mechanisms of lncRNA function 
 
 
Function 
 
Specific lncRNA mechanism 
 
Reference 
 
Epigenetic and chromatin 
modification 
 
XIST: Exclusively expressed on the inactive X 
chromosome, recruits PRC2 to X-chromosome 
inactivation center (XIC) for gene silencing  
 
 
43 
 
 
Sponge for miRNAs 
 
H19: Contains 4 Let-7 binding sites throughout 
transcript body to competitively bind and down-
regulate Let-7 in Ago2 dependent manner. 
 
 
51 
 
 
Messenger RNA processing and 
protein translation 
 
ZEB2-AS: Transcribed antisense to ZEB2 mRNA, 
binds ZEB2 transcript and prevents splicing of 5’ 
intron preventing protein translation. 
 
 
57 
 
 
Enhancers and transcriptional 
activation 
 
CCAT2: Transcribed in enhancer region ~334 kb 
upstream of C-MYC transcriptional start site, 
recruits TCF7L2 to C-MYC promoter. 
 
 
61 
 
 
Decoy for protein binding 
 
PANDA: Induced in DNA damage response, binds 
and sequesters transcription factor NF-YA to 
prevent induction of pro-apoptotic gene targets 
 
 
63 
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hypothesis [50]. LncRNAs can interact with miRNAs through these repeat MREs along 
the length of the transcript to influence global gene expression. For example, within the 
body of lncRNA H19 resides 4 canonical and noncanonical MREs for Let-7 [51]. It was 
demonstrated that enforced expression of H19 results in more Let-7 binding at these 
MREs in an Ago2-dependent manner. Through competitive binding and sequestering of 
Let-7, downstream targets of Let-7 such as DICER and HMGA2 increased their 
expression [51]. 
Linc-ROR, a regulator of reprogramming, can also act as a sponge and shares 
MREs with several miRNAs that target the core transcription factors in maintaining 
embryonic stem cells. [52, 53]. Expression patterns of linc-ROR are consistent and 
associate with undifferentiated status. Linc-ROR contains MREs for miR-145, miR-181, 
and miR-99-3p, which target Oct4, Nanog, and Sox2. Enforced expression of linc-ROR 
competitively binds these miRNAs relieving target repression, enhancing protein 
expression of these core transcription factors.  Loss of linc-ROR leads to decreased 
expression of Oct4, Nanog, and Sox2 and movement towards the differentiated state 
[53]. 
 
Messenger RNA Processing and Protein Translation. LncRNAs can 
physically interact with mRNAs to influence stability of the transcript or translation in 
dynamic ways [54, 55]. This relationship is especially apparent in the case of protein 
coding genes which contain overlapping natural antisense transcripts (NATs). Uchl1 
protein gene overlaps with antisense lncRNA Uchl1-AS at the 5’ region and also 
contains an inverted SINE2B repeat element downstream [56]. In the stress response or 
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using rapamycin treatment to induce stress, Uchl1-AS will rapidly shuttle from the 
nucleus to the cytosol where it binds to and stabilizes the Uchl1 mRNA transcript along 
the 5’ UTR region leading to increased translation. The detailed underlying mechanism 
is not very well understood, but the SINE2B element is critical for enhanced translation 
during this process, indicating a possible novel function for transposable elements 
within the genome [56]. 
In another example, Snail1-induced epithelial to mesenchymal transition (EMT) 
does not activate Zeb2 mRNA transcription, but rather promotes Zeb2 translation 
through splicing of a large intron at the 5’ UTR region. This intron contains an internal 
ribosome entry site (IRES) necessary for the expression of Zeb2. Maintenance of 5'-
UTR Zeb2 intron is dependent on the expression of Zeb2-AS1 that overlaps the 5' splice 
site in the intron. In the non-EMT state this intron is spliced out, which does not affect 
mRNA level yet does prevent protein translation. In the case of Snail1-induced EMT, 
Zeb2-AS1 is transcribed and its complimentary base pairs with the 5’ UTR of Zeb2  
prevents splicing of the 5’ IRES sequence allowing for Zeb2 translation [57]. 
 
Enhancers and transcriptional activation. Enhancers are regulatory DNA 
elements that activate gene transcription in “cis” through chromosomal looping and 
recruitment of cofactors [58, 59]. It is now emerging that these regulatory regions 
frequently contain lncRNAs which have target gene specificity and promote cofactor 
recruitment. In one study, enhancer-associated ncRNA-a7 was characterized as being 
able to specifically regulate SNAI1 transcription, yet had no relationship to RNF114, 
UBE2VI, TMEM189, or CEBPB which reside within the same 100 kb radius [60]. It was 
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also shown that SNAI1 migration phenotype was driven through ncRNA-a7 providing 
strong evidence that lncRNAs play a key regulatory role in gene expression and 
downstream biological processes [60]. 
Another lncRNA CCAT2, which locates ~334 kb away from C-MYC 
transcriptional start site, was shown to be over-expressed in colorectal cancers and 
promote chromosomal instability, invasion, and metastasis [61]. CCAT2 binds to 
transcription factor TCF7L2 for recruitment to the enhancer region and results in 
activation of C-MYC transcription through chromosomal looping and interaction at the 
promoter. Interestingly, CCAT2 has a single nucleotide polymorphism (SNP) that 
associates with increased risk of developing colon cancer. This study suggests that this 
SNP is functional through the RNA product, and enhances TCF7L2 recruitment to the 
C-MYC promoter prompting a paradigm shift that SNPs are typically functional through 
DNA elements [61].  
 
Decoy for protein binding. LncRNAs can also function as decoys through 
binding protein targets and thereby preventing normal function and localization of the 
protein. For example, in response to DNA damage a subset of lncRNAs will be induced 
in a p53-dependent manner including 2 bidirectional transcripts upstream of the p21 
promoter, lincRNA-p21 and PANDA [62, 63]. During this response PANDA will bind to 
the transcription factor NF-YA and prevent its localization at promoters of pro-apoptotic 
target genes. Thus, PANDA allows for cell cycle arrest and DNA repair rather than 
programmed cell death in the p53 response [63]. Another example can be seen in extra-
coding CEBPA lncRNA (termed ecCEBPA), a ~4.5kb transcript encompassing the 
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entire ~2.6 kb portion of the CEBPA gene in the sense direction [64]. When ecCEBPA is 
expressed it will competitively bind and exclude DNMT1 for the occupying chromatin at 
the CEBPA promoter, thus preventing DNA methylation and activating transcription of 
the CEBPA [64]. 
 
LncRNAs in Cancer and Malignancy 
 
LncRNAs regulate genes that participate in a wide range of biological processes, 
and for this reason they can act as oncogenes and tumor suppressors. Aberrant 
expression of lncRNA can be a deciding point in cancer etiology, promote tumor onset 
and disease progression, as well as drive metastasis. LncRNAs are also a novel and 
untapped resource for pathological and clinical utility for use as novel biomarkers. 
Although a number of lncRNAs have been associated with cancer in literature, there is a 
clear need for further identification and characterization of more candidates. The 
following section will discuss the function and clinical significance of specific lncRNAs 
reported in human cancer to date. 
  
 HOTAIR. HOTAIR, as discussed above, locates on chromosome 12 and is 
responsible for “trans” silencing the HoxD genes of chromosome 2 through recruitment 
of PRC2 complex [48]. HOTAIR expression has been shown to be up-regulated in both 
primary and metastatic breast cancers, in some cases as high 2,000-fold over-
expression. Furthermore, the elevated expression correlates with increased risk of 
metastasis, as well as poor metastasis-free and overall survival [65]. In vitro studies 
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demonstrate that knockdown of HOTAIR can inhibit invasive capacity. While in vivo, 
enforced expression of HOTAIR results in a greater capacity for breast cancer cells to 
colonize the lung following tail vein injection [65].  
In non-small cell lung cancer (NSCLC), HOTAIR has been shown to have 
elevated expression levels when comparing 42 lung carcinomas to matched normal 
tissues [66]. Elevated HOTAIR in NSCLC patients also associates with late stage tumor, 
positive lymph node metastasis, and poor overall survival. This study also demonstrates 
that HOTAIR can control cell migration, invasion, and metastasis in vitro and in vivo, 
and shows that knockdown of HOTAIR leads to apoptosis. Depletion of HOTAIR 
resulted in significant loss of expression of known metastasis promoting genes MMP2 
and MMP9, and increased expression of HOXA5, which has been shown to be 
important in inhibiting lung cancer metastasis [66]. 
A recent study shows that in renal carcinoma cells HOTAIR is inversely 
correlated in expression with miR-141 [67]. This study also shows that HOTAIR plays a 
critical role in promoting migration, invasion, and survival in renal carcinoma. 
Interestingly, enforced expression of miR-141 results in significant loss of HOTAIR 
expression, reduced invasive phenotypes, and increased apoptosis. Further 
investigation revealed that HOTAIR is a bona fide miR-141 target in an AGO2 
dependent manner. This study illustrates the dynamic relationship between ncRNA 
species regulating each other, and their potential role in kidney cancer [67]. 
 
XIST. In one study the contribution of XIST to hematological cancers using a 
conditional knockout mouse model was evaluated. The majority of the females in which 
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XIST is conditionally removed from cells in the blood compartment results in aggressive 
and rapid onset of multi-lineage hyperproliferations, myelodysplasia, and 
myeloproliferative neoplasms [68]. These results suggest a potent tumor suppressor 
role for XIST in hematopoietic stem cells and potentially other tissues. Deletion of XIST 
resulted in X chromosome reactivation and aberrant gene expression in several major 
tumor suppressive pathways contributing to the rapid onset of disease [68]. 
A second study used microarray technology to compare global changes in RNA 
expression in primary ovarian tumor to recurrent ovarian tumors after chemotherapy 
[69]. Interestingly, in recurrent ovarian cancer XIST was the most significantly 
downregulated gene in comparison to primary tumor [69]. From a therapeutic standpoint, 
this suggests that XIST can potentially play a role in sensitizing patients to taxol and 
cisplatin based chemotherapies. XIST can also serve as a marker for chemoresistant 
ovarian cancer. 
XIST has also been linked to the BRCA1 tumor suppressor gene in patients with 
breast or/and ovarian cancers. Initial reports indicated that breast cancers with deficient 
BRCA1 expression or function have defects in X chromosome inactivation, and 
enforced expression of BRCA1 gene can initiate XIST expression [70]. This view was 
later challenged using a BRCA1 conditional knockout mouse model which 
demonstrated that depleting BRCA1 had no affect on X inactivation and gene dosing, as 
well as showed no evidence of BRCA1 and XIST colocalization [71]. The relationship 
between BRCA1 and XIST in breast cancer will require future investigation to be better 
established. 
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MEG3. Maternally expressed gene 3 (MEG3), a paternally imprinted gene 
comprised of 10 exons, is expressed in many normal tissues [72]. There are 12 different 
MEG3 gene transcripts, generated by alternative splicing. They contain the common 
exons 1-3 and exons 8-10, but each uses one or more exons 4-7 in a different 
combination in the middle. All MEG3 RNA isoforms contain three distinct secondary 
folding motifs M1, M2, and M3 that are critical for activation of p53.  MEG3 isoform 
expression patterns are tissue and cell type specific. However, each isoform stimulates 
p53-mediated transactivation and suppresses tumor cell growth.  MEG3 retains the 
ability to activate p53 in spite of replacing regions unrelated to M1, M2, or M3, thus 
provides evidence that a proper folding structure of the MEG3 RNA molecule is critical 
for its biological functions and that only short stretches of sequence conservation are 
vital to maintain function [73]. In addition to transcriptionally activating p53, MEG3 can 
also enhance binding of p53 at target gene promoters including GDF15 [74]. MEG3 
expression is dramatically lost in several human cancers [73]. Reintroduction of MEG3 
into NSCLC cells was able to slow colony formation capacity and cell proliferation [73]. 
In panel of hepatocellular carcinoma (HCC) cells MEG3 is frequently 
downregulated, and enforced expression of MEG3 was able to slow cell proliferation, 
inhibit anchorage independent growth, and promote apoptosis [75]. This same study 
also demonstrated that maternal allele of MEG3 is hypermethylated in a DNMT1 and 
DNMT3b dependent manner. Interestingly, miR-29a expression is also commonly lost in 
HCC and DMNT1 and DNMT3b are direct targets of miR-29a. Loss of miR-29a results 
in aberrantly increased DMNT1/3b expression in HCC and provides a novel mechanism 
for MEG3 downregulation due to hypermethylation at the promoter [75]. 
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ANRIL. Antisense noncoding RNA in the INK4 locus (ANRIL) was initially 
identified as being deleted in the germ-line deletion of the 9p21 gene cluster [76]. This 
gene cluster contains several important tumor suppressor genes including, p14ARF, 
p15INK4B, and p16INK4A that are deleted along with ANRIL across ~ 403 kb region 
and results in cancer predispositions [77-79]. ANRIL locates in the antisense direction 
and overlaps with the p14ARF promoter and 2 exons of the p15INK4B gene body [76]. 
Although initial reports identified this transcript as associated with deletion, later reports 
suggest that ANRIL over-expression can also drive cancers [80, 81]. 
Elevated expression of ANRIL was detected in prostate cancer and inhibiting 
ANRIL expression resulted in increased INK4A and INK4B gene products, denoting a 
transcriptional repression in “cis”. In this same study it was shown that ANRIL can bind 
to CBX7 component of the PRC1 repressive complex and epigenetically silence the 
associated tumor suppressive genes on 9p21 gene locus [80].  ANRIL is also elevated 
human gastric cancers and associates with poor overall survival. This same study 
demonstrated that ANRIL can silence oncogenic miRNAs, including miR-99a and miR-
449a, through binding to the components of PRC2 transcriptional repression complex 
[81]. 
 
Emerging lncRNAs in cancer. The 8q24 chromosomal amplification associates 
with increased risk for several cancers. Linked within this region resides a gene desert 
containing no protein coding genes in addition to the C-MYC oncoprotein [82-85]. 
Several lncRNAs (CCAT2, Carlo-5, and PVT1) have been identified within this region 
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and regulate C-MYC expression through a variety of mechanisms including 
transcriptional activation, enhancer-associated function, and protein stability [61, 86, 87].  
Another interesting lncRNA, FAL1, has recently been identified as locating in a 
focally amplified chromosome 1q21 region across several epithelial cancers including 
breast and ovarian [88]. FAL1 binds to PRC1 core subunit BMI1 to transcriptionally 
repress tumor suppressor gene p21. Interestingly, FAL1 is a predictor of poor overall 
survival in ovarian cancer patient and elevated FAL1 closely associates with 
chromosome 1q21 DNA copy number gain [88]. 
TGFβ-induced lncRNA-ATB is also emerging as an important driver in EMT and 
metastasis in liver cancer. LncRNA-ATB is a potent driver of the EMT by acting as 
miRNA sponge for the miR200 family [89]. This family is the master regulator of ZEB1/2 
expression through 3’ UTR mediated repression in an Ago2 dependent manner. Also, 
lncRNA-ATB promotes cell proliferation and distant colonization through directly binding 
and stabilizing IL-11 mRNA resulting in activation of phospho-STAT3 [89]. 
 
TGFβ Signaling Pathway 
 
TGFβ  Signaling Pathway and Ligands. The TGFβ signaling pathway is 
dynamic and involves in a variety of normal cellular programs such as cell differentiation, 
proliferation, inflammation, tissue morphogenesis, regeneration, and maintenance 
(Figure 3). It has become clear that TGFβ pathway is dependent on cellular context. For 
example, depending on cell type and tissue of origin the TGFβ pathway can elicit a 
radically different, and sometimes opposite functional response [90]. Significant 
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research efforts have been put forth in defining the related cytokines, receptors, and 
intracellular signaling molecules in order to establish the pathway, which made it 
possible to study its functional role in a given cellular context. We now have a better 
understanding of the pleiotropic effects elicited by the TGFβ pathway. 
The TGFβ related ligands and cytokines consist of 2 subfamilies (including 42 
ligands and over 300 target genes) as categorized by sequence homology and 
downstream effectors in the pathway [91]. The first family includes the TGFβ’s, Activin, 
and Nodal ligands, while the second family consists of the BMPs (bone morphogenetic 
proteins) and MISs (muellerian inhibiting substances) [92]. Both families work in a 
variety of developmental cellular functions such as embryogenesis, osteogenesis, and 
hormone regulation. [93-95] The TGFβ monomer contains a conserved “cysteine knot” 
which consists of several beta strands held together by three tight disulfide bridges. 
These monomers typically take on the active dimerized form that is held via 
hydrophobic interactions and disulfide bridges. [96] Ligand traps are a group of proteins 
that regulate the TGFβ ligands and cytokines access to receptors. These traps can 
promote or inhibit the ligand/receptor interaction and provides a mechanism of 
specificity. [97] 
 
TGFβ Signaling Pathway Receptors. The receptors associated with TGFβ 
pathway are serine/threonine kinases and are referred to as type I (7 receptors) or type 
II (5 receptors). These receptor kinases contain an extracellular N-terminal ligand 
binding domain, a transmembrane domain, and a C-terminal kinase signaling domain. 
Type I receptors are 53-KD proteins that contain a conserved SGSGSG motif, called 
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GS domain, located N-terminally and in close proximity to the kinase domain. This 
domain on type I receptor is directly phosphorylated by type II receptor resulting in 
activation of dimeric complex, and therefore a heterodimer is critical for activation. [98] 
There are 2 distinctive ligand-receptor interactions which are distinguished by the 2 
superfamilies of ligands mentioned above. These distinctions refer to each subfamilies 
affinity to TGFβ receptor types, for example TGFβ’s, Activins, and Nodal ligands 
preferentially bind to type II receptor and do not interact with isolated type I receptors, 
while BMPs prefer to interact and have high affinity for type I receptors. [99] 
 
TGFβ  Signaling Pathway SMAD Proteins. The intracellular effector and 
regulatory molecules of the TGFβ pathway are the SMAD family proteins. Three classes 
of SMAD proteins exist in humans, receptor regulated SMADs or “R-SMADs” (includes 
SMAD1, 2, 3, 5, 8/9), co-mediator SMAD or “co-SMAD” (SMAD4), and inhibitory SMAD 
or “I-SMADs” (SMAD6, 7) (Figure 4). R-SMADs are the direct substrates of receptor 
mediated phosphorylation by type I receptors. SMAD2 and SMAD3 are activated in 
response to TGFβ ligand subfamily, while SMAD1, SMAD5, and SMAD8 respond to 
BMP subfamily of ligands. [92] 
R-SMADs are typically about 400-500 amino acids, contain a conserved N- 
terminal MH1 (MAD-homology 1) domain (40-95% conservation across R-SMADs), C- 
terminal MH2 (MAD-homology 2) domain (38-98% conservation), and have 2 conserved 
structural domain to provide secondary structure.  [100] The MH1 domain functions as 
the DNA recognition and binding element while MH2 domain facilitates homo- or hetero- 
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Figure 3. The TGFβ  signaling pathway and associated molecules. The TGFβ 
pathway consists of ligands, receptors, and intracellular signaling molecules called 
SMADs to influence target gene expression. The TGFβ (transforming growth factor 
beta) and BMP (bone morphogenic protein) ligands bind type I and II TGFβ receptors to 
initiate R-SMAD (regulatory) and co-SMAD (cooperative) signaling cascade. Inhibitory 
SMADs (I-SMADs) can directly bind to and inhibit the receptors through a negative 
feedback loop. 
 
 
oligermization to promote dimer activation. The R-SMADs also contain an SXS motif at 
the C-terminal region and these serine residues are critical for activation [101]. Two 
members of the Hecht-family of E3 ubiquitin ligases, SMURF1 and SMURF2, can target 
and negatively regulate the R-SMADs and receptors [102, 103]. Subsequent R-SMAD 
activation via type I or type II TGFβ receptor, homo-oligomerization will first occur, and 
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downstream with co-SMAD4 as a hetero-dimer or -trimer. The active heterocomplex of 
R-SMAD/co-SMAD4 can then translocate to the nucleus and activate transcription of 
numerous target genes. Target gene transcription and functional outcome occurs 
through the dynamic interactions with the MH1 and MH2 domains as well as the 
recruitment of other transcriptional mediators. 
Negative regulation of the TGFβ pathway is a critical feedback process and 
tightly regulated mechanism to haul over-active signaling. Two members of the Hecht-
family of E3 ubiquitin ligases, SMURF1 and SMURF2, can target and negatively 
regulate the R-SMADs and type I and II receptors [103]. Specifically SMAD1 and 
SMAD5 is a substrate for SMURF1 ubiquitin ligase activity. [104] SMURF2, which 
contains significant homology to SMURF1, can preferentially inhibit SMAD1 and 
SMAD2 [105, 106]. Inhibitory SMAD7 plays a critical role as co-regulator in this process. 
Once TGFβ pathway is activated, SMAD7 will translocate from the nucleus to the 
cytosol to locate at the plasma membrane through an unknown mechanism. As a result 
of this translocation, SMAD7 can form complexes with both SMURF1 and SMURF2 and 
become tethered to the membrane to directly bind type I receptors, including those 
involved in the late endosomal compartments. Binding of SMAD7 to type I receptor will 
competitively inhibit phosphorylation of R-SMADs [106]. Also, recruitment of SMURFs to 
the membrane will promote E3 ubiquitinase activity to directly facilitate degradation of 
the receptors. This negative feedback look is perpetuated and balanced given that 
during TGFβ activation SMAD7 is itself ubiquitated and degraded, yet is also a 
transcriptionally activated target gene [108]. This ensures proper SMAD7 turnover and 
dosage during the response. 
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Figure 4. The SMAD family of proteins. The SMAD family is comprised of R-SMADS 
(regulatory), Co-SMAD (cooperative), and I-SMAD3 (inhibitory) and function through 
varying regions N-terminal MH1 domain (MAD homology-1), middle linker region, and 
C-terminal MH2 domain. Abbreviations: NLS (nuclear localization signal), P-Y (proline-
tyrosine), SXS (serine-X-serine), NES (nuclear export signal), SAD (SMAD activation 
domain). Figure adapted from Moustakas et. al. [107]. 
 
 
TGFβ-associated phenotypes and genes 
 
Epithelial to Mesenchymal Transition (EMT). The epithelial to mesenchymal 
transition (EMT) is a highly organized process facilitated through distinct biological 
pathways that shift a polarized epithelial cell to a mesenchymal phenotype. 
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Mesenchymal phenotypes associate with increased motility and invasion, 
production of extracellular matrix components (fibroblast-like), and resistance to 
apoptosis [109, 110]. EMT exemplifies the inherent ability of epithelial cell plasticity and 
how dynamic interactions from extracellular components can influence terminally 
differentiated tissue to promote cancer phenotypes. Ultimately, this process is the 
driving force in which a cancer cells can degrade the basement membrane and gain 
access to the blood stream and initiate metastasis (Figure 5). 
It is important to note that the process of EMT is initial breaching of the basement 
membrane and escape from the primary site. Downstream, other process such as 
resistance to anoikis (anchorage-independent cell death) and mesenchymal to epithelial 
transition (MET) must still take place for a cell to successfully colonize and form a 
secondary carcinoma. The process of EMT is considered a fundamental hallmark of 
cancer, and further understanding this process is critical given the consequences that 
once cells leave the primary site acquire these aggressive characteristics to enable 
metastasis [111]. 
 
Changes in Gene Expression Associated with EMT. There are several 
fundamental gene changes associated with conversion of an epithelial cell to more 
mesenchymal cell. Down-regulation of cell to cell adhesion and tight junction molecules 
like e-cadherin (CHD1) and ZO-1 which stabilize and immobilize the epithelium is 
typically characteristic to early EMT. This down-regulation is also true for several other 
more specific cytoskeletal and adherent molecules like claudins, occludins, 
desmoplakins, and cytokeratins [112]. At the same time as there is a loss of adherent 
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Figure 5. The epithelial to mesenchymal transition (EMT) in breast cancer. In 
breast cancer progression, the normal epithelial cell layer within the breast duct will 
become hyperplastic and eventually lead to an uncontrollable proliferative mass known 
as carcinoma. The primary carcinoma will fill the duct while at the edge of the tumor 
some cells will break through the basement membrane. These cells are considered to 
have undergone the epithelial to mesenchymal transition (EMT). These invasive cells 
can gain access to blood vessels and travel to distant organs in the body to colonize 
and form secondary carcinomas. This process is referred to as mesenchymal to 
epithelial transition (MET) and metastasis. Adapted from Kalluri and Weinberg [110]. 
 
molecules, there is an up-regulation of another set of molecules responsible for motion 
and invasive potential. There is a “cadherin switch” from E-cadherin to N-cadherin 
expression which decreases cell to cell contact. The up-regulation of N-cadherin not 
only affects adhesion qualities on cell surface, but also shifts signaling pathways inside 
the cell to promote migration and invasion. These pathways and interactions include β-
catenin, receptor tyrosine kinases (RTKs), platelet derived growth factor (PDGF), 
fibroblast growth factor receptors (FGFRs), and SRC family kinases [113-115]. In 
addition, several other genes such as vimentin, fibronectin, collagen I/IV, lamin I, and 
matrix metalloproteinases MMP2/MMP9 are up-regulated enhancing cell’s ability to 
break through the basement membrane and ECM components (Figure 6) [104]. 
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There are also several established transcription factors that drive EMT including 
ZEB1/2, SNAI1, and basic helix loop helix transcription factors (bHLH). ZEB1/2 can 
transcriptionally repress or activate several target genes to promote EMT in cancer 
through it’s interaction with DNA regulatory sequences called E-boxes [116]. ZEB1 can 
interact with c-terminal-binding protein (CTBP) or switch sucrose/non fermentable 
protein (SWI/SNF) protein BRG1 to transcriptionally repress e-cadherin [104]. SNAI1 
(SNAIL) and SNAI2 (SLUG) are known to drive mesenchymal phenotype during 
embyrogenesis and development and can become reactivated in cancer [117]. 
Similar to ZEB1/2 function, SNAI1/2 can bind to E-boxes through their zinc finger 
motifs to shut down E-cadherin transcription. Once bound to E-cadherin promoter, 
SNAIL can recruit polycomb recessive complex 2 (PRC2) which contains several 
subunits histone methyltransferase, histone demethylases, histone deacetylases, and 
co-repressors. Together the subunits of PRC2 work through modifying histones and 
chromatin to coordinate transcriptional repression [104]. The bHLH transcription factors 
that play a major role in contributing to EMT are TWIST1 and TWIST2. TWIST1/2 can 
repress E-cadherin expression independently from SNAIL and also transcriptional 
activate several mesenchymal genes such as N-cadherin [116]. All three of these 
transcription factors can be up-regulated via several mechanisms associated with tumor 
proliferation and tumor microenvironment, including but not limited to elevated levels of 
TGFβ, hypoxia inducible factor 1α (HIF1α), WNT signaling pathway, and RAS-MAPK 
signaling pathway [118-121]. 
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Figure 6. EMT-associated markers and phenotypes. Throughout the process of EMT 
gene signatures and cell phenotype will change from epithelial status to a more 
mesenchymal state. Characteristic expression of epithelial markers such as e-cadherin, 
ZO-1, and specific cytokeratins will be down-regulated, and the TGFβ-induced transition 
with trigger a switch towards mesenchymal markers such as vimentin, fibronectin, and 
Zeb1/2. The epithelial cells will phenotypically appear more spindle-like, contain fewer 
tight junctions, and become more motile and invasive. 
 
 
Cancer Stem Cells (CSCs). Historically, clinicians have observed in that giving a 
single agent therapy to a patient a subset of cells in the primary tumor are sensitive to 
the treatment while others remain resistant. It is now established that a primary tumor is 
not composed of a monoclonal mass of cells with equal cellular make-up and 
constituents, but rather tumor heterogeneity exists within the mass [122]. In fact a 
primary tumor is not only composed of genetically and phenotypically distinct carcinoma 
cells, but is also composed of endothelial, stromal, immune, and hematopoietic cells 
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that function as a dynamic system. Terminally, well-differentiated epithelial cells are 
typically thought of as being functional, healthy adult tissue. Therefore, the term “cancer 
stem cell” in part refers to cancer’s ability to revert from this well-differentiated state 
back to a more “stem-like” state. A loose definition for CSCs is a population of cancer 
cells that can be isolated with a capacity for long-term repopulation and self-renewal of 
the original tumor. [123, 124] 
Functionally, CSCs can initiate tumor formation in xenograft model, self-renew 
through serial passaging of spheres, and spawn daughter cells which can proliferate 
and also form new tumor, although this tumor is may be different from parental [104, 
125]. The origin of CSCs remains up to debate and several theories have surfaced. One 
known as the hierarchal model proposes that a small subset of CSCs exists within the 
tumor population, and these cells obtain the characteristics for tumor propagation as 
well as self renewal of more CSCs. In contrast the stochastic model assumes that all 
cells within the tumor have the ability for tumor initiation and these qualities are 
intrinsically determined by several factors and influenced by surrounding environment 
(Figure 7) [124]. 
 
Breast Cancer Stem Cells (BCSCs). BCSCs originate in the breast and obtain 
the properties described above. Initial reports of BCSCs utilized cell surface markers 
CD44 and CD24 status to distinguish the stem cell population. BCSCs are typically 
defined as population of cells that is CD44+/CD24-. In one study, total breast cancer 
cells from human patient tumor were sorted for CD44+/CD24- population or cells 
without this surface receptor status. In eight out of nine patients as few as 100 cells 
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isolated with CD44+/CD24- were able to establish a xenograft tumor in mice, while tens 
of thousands of cells were required if there was alternate cell surface status [126]. The 
classification of BCSCs based solely on CD44 and CD24 status remains up to debate, 
as several reports claim that elevated CD24 associates with poorer patient outcome 
[127, 128] 
Another cellular marker that is widely used to distinguish BCSCs as well as other 
CSCs is alcohol dehydrogenase isoform 1, ALDH1. This enzyme normally catalyzes 
oxidation of intracellular aldehydes in the process of normal stem cell differentiation 
[129]. Interestingly, the population of ALHD1+ cells sorted from total CD44+/CD24- 
population is only about 1%. However, if CD44+/CD24- population is also then sorted 
for ALDH1+, these cells obtain ~5-fold greater tumor initiating capacity as compared to 
those sorted for CD44+/CD24- alone [130]. In addition to this, it has been reported that 
patients with elevated levels of ALDH1 in tumor have overall poorer survival [131]. 
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Figure 7. The “Stochastic” and “Hierarchal” models of cancer stems cells. (CSCs). 
There are 2 theories that exist for CSCs referred to as stochastic and hierarchical 
models. The stochastic model suggests that cancer cells are dynamic, and through 
gene expression changes any cell can acquire properties necessary to initiate de novo 
tumor formation. The hierarchal model suggests that the CSCs are more static and fixed, 
and only a few distinct cells obtain the potential to be tumor initiating. 
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CHAPTER 2 
Identification of lncRNAs regulated by TFGβ  in mouse mammary epithelia and 
strategy to identify human orthologs 
 
Introduction 
 
It has been well documented that metastasis is the most common cause of death 
from human cancer.  TGFβ has been shown to play a pivotal role in cell migration, 
invasion, EMT and metastasis.  A number of protein coding genes and miRNAs have 
been shown to be regulated by TGFβ and mediate TGFβ action and phenotypes.  
However, lncRNAs regulated by TGFβ and their role in EMT and tumor metastasis has 
not been well documented. 
The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) is 
now well established as a key negative regulator of EMT through targeting ZEB1 and 
ZEB2, considered to be key drivers in the process [132, 133]. Interestingly, ZEB1 can 
also negatively feedback on miR-200 family through direct binding to the promoter 
regions and transcriptionally repress expression through the recruitment of co-factors. 
[134] Although loss of miR-200 family results in increased EMT and intravasation from 
primary site, in a not well understood process re-expression of miR-200 has been 
shown to be critical for MET and colonization at distant site. For example, there is 
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higher miR-200 expression in the highly metastatic mouse cell line 4T1, which is 
capable of colonizing and forming macrometastases, compared to 4T07 which can form 
micrometastases but not colonization. Ectopic expression of miR-200 in 4T07 cell line 
enhanced MET and formation of macrometastasis at distant site, primarily through 
targeting Sec23a [135, 136]. Other miRNAs such as MYC induced miR-9, TGFβ 
induced miR-155, and miR-221/222 cluster have been shown to be potent promoters of 
EMT through direct targeting of E-cadherin, RHOA, and TRPS1 [137-139]. In 2008, the 
first connection between lncRNA, Zeb2-AS, as a mediator of EMT was elegantly 
described (mentioned above). Recently, a TGFβ-activated lncRNA, lncRNA-ATB, has 
been shown to play an important role in TGFβ-mediated EMT by acting as a sponge for 
miR-200 family. LncRNA-ATB is significantly up-regulated in response to TGFβ and 
contains 3 bonafide miRNA binding sites for miR-200. These sites can act as a miRNA 
sponge to bind and sequester miR200s, and provide a novel mechanism for ZEB1/2 up-
regulation and initiate EMT [89]. 
Noncoding RNAs can have a significant influence in the biological processes 
associated with cancer stems cells such as pluripotency, self renewal, and 
differentiation. In several cancers, including pancreatic, prostate, and gastric, the p53-
induced miR-34 family (miR-34a, miR-34b, and miR-34c) has demonstrated to suppress 
tumor formation and tumor initiating cells [140-142]. miR-34 directly targets several key 
tumor promoting genes which likely all contribute to inhibiting this process, such as 
CD44, C-MYC, BCL-2, MET, CDK4/6, and Cyclin E2 [140, 141, 143-145]. Let-7 and 
miR-200c have also been shown to be down-regulated in CSCs compared to 
differentiated state and non-CSC tumor cells [146, 147]. The functional role of lncRNAs 
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contributing to CSCs has not been very well studied and established. However, there 
are certainly candidate lncRNA genes that can contribute to tumor initiating population 
given there implications in other studies. For example, lncRNA H19 acts a miRNA 
sponge for Let7-family and inhibit Let-7 function leading to upregualtion of Let-7 target 
genes. [51] Given that let-7 loss has previously been implicated in driving CSCs, H19 
likely contributes to this process. 
It is well established that the NMuMG cell line undergoes EMT and takes upon 
more fibroblastic features if treated with TGFβ for 24 hours. We have isolated total RNA 
from NMuMG cells treated with vehicle (DMSO) or TGFβ for 24 hours. The RNA was 
reverse transcribed, end-labeled with digoxigenin, and hybridized to NCode Mouse 
Non-coding RNA Microarray (Invitrogen). This microarray contains high-density oligo 
based probes designed to interrogate 10,802 unique putative mouse lncRNAs, as well 
as 25,179 mRNAs from the RefSeq database. 
Although the majority of lncRNAs are not conserved from mouse to human, we 
hypothesized that a small fraction of them are conserved and have a strong functionality. 
Retention of sequence through evolutionary pressures has been very important for 
preservation of structure and function in proteins, and it is possible this same 
occurrence has taken place among lncRNAs. Furthermore, of the significantly induced 
lncRNAs  by TGFβ in mouse, we implemented a system based on 4 criteria to predict a 
strong potential for ortholog lncRNA in human. Using this strategy, we were able to 
successfully predict 10 human ortholog lncRNAs and detect expression of 9. Three of 
these transcripts were also regulated by TGFβ in human primary mammary epithelial 
cell line HMEC.  We further investigated these transcripts. 
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Results 
 
Profile of lncRNA expression in TGFβ-induced EMT in NMuMG cells.  Using 
the widely employed NMuMG mammary epithelial cells as a model to study TGFβ-
induced EMT, we have previously shown that TGFβ up-regulates ncRNA BIC, which 
processes into miR-155 to contribute to the process of EMT [138]. Therefore, we 
hypothesized that TGFβ could similarly regulate lncRNAs that control EMT-associated 
phenotypes. To address this, we treated NMuMG cells with vehicle or TGFβ (5 ng/ml) 
for 24 hours to induce EMT (Fig 8A).  Total RNA was labeled with digoxigenin and 
hybridized to NCode Mouse Noncoding RNA Microarray.  This is a high density oligo 
array that contains lncRNAs and protein coding genes in order to study the dynamic 
expression of a large subset of lncRNAs and associated protein coding genes within the 
same biological sample.  This array contains 2 replicates for each gene per sample to 
ensure signal is consistent and reliable. We have plotted relative intensity signals of 
replicate spots for lncRNAs in control cell and TGFβ-induced EMT to assess the 
consistency of signal for lncRNA within given sample. Linear regression analysis shows 
significance for both vehicle and TGFβ treated replicates indicating that signal within our 
samples is consistent (Fig 8B-C). The microarray contains replicates for 10,802 
lncRNAs in which signal was normalized, averaged, and plotted to assess overall 
changes in expression in vehicle versus TGFβ induced EMT (Fig 8D).  
We determined that lncRNA expression was significantly changed if average 
signal of replicates changed ≥2-fold from vehicle to TGFβ treated samples (Fig 9A). 
  
 40 
 
 
 
Figure 8. LncRNA expression profile of TGFβ-induced EMT in NMuMG cells.  (A) 
TGFβ induces cell morphological change of EMT in NMuMG cells. The cells were 
treated with vehicle (left) or 5 ng/ml TGFβ (right) for 24 hours and then photographed.  
(B - C) Linear regression analysis of lncRNAs in 2 replicates after vehicle (B) and TGFβ 
(C) treatment of NMuMG cells for 24 hours.  (D) Scatter plot analysis comparing all 
lncRNA changes vehicle vs. TGFβ-treated NMuMG.  Note: red and green dots 
represent up-regulated and down-regulated lncRNAs, respectively. 
 
 
Using ≥2-fold change as criteria, 633 lncRNAs were down-regulated and 680 lncRNAs 
were up-regulated following TGFβ-induced EMT (Fig 9B).  Furthermore, we confirmed 
the expression of several top changed lncRNAs by real-time PCR (Fig 9C-D). Tables 3 
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and 4 summarize top 15 up-regulated and 15 down-regulated lncRNAs.  (Tables 3 and 
4). 
 
 
 
Figure 9. Verification of TGFβ-regulated lncRNAs. (A) Heatmap and (B) diagram 
representations of dysregulated lncRNAs between vehicle- and TGFβ-treated NMuMG 
cells.  (C)  Real-time PCR analysis of representative TGFβ-upregulated and (D) 
downregulated lncRNAs. 
 
In 25,179 mRNAs represented on the chip, signal for each probe was averaged 
and plotted to assess overall changes in EMT response (Fig 10A). Genes were 
considered significantly changed if average fold change was greater than 2-fold. In total, 
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1,096 genes increased and 2,220 decreased expression upon TGFβ-induced EMT (Fig 
10B).  Further RT-qPCR validation showed significant changes of several top scoring 
and established typical TGFβ target genes including Col1a1, Ctgf, Itga5, Serpine1, 
Kif12, Rbp4, ect., indicating that the lncRNA and mRNA data generated in this study are 
dependable (Fig 10 C-D). 
 
Strategy used to discover conserved human ortholog lncRNAs. In total, 680 
lncRNAs were up-regulated 2-fold or greater. The ultimate goal of this project is to 
identify lncRNAs important in driving human cancer development and/or metastasis. 
Therefore from the data generated using the mouse lncRNA microarray, we developed 
a strategy to predict mouse lncRNAs with a strong potential to have a conserved human 
ortholog. To do this, we designed a workflow to which we subjected significantly TGFβ-
induced mouse lncRNAs  (Figure 11). These mouse lncRNAs had to fit 4 criteria or be 
thrown out. If all 4 criteria were met, we considered these transcripts strong candidates 
to be conserved in human and potentially across other species. In this study, we 
focused on transcripts induced and not repressed (Figure 11), as these genes could be 
knocked down for functional analysis in both mouse and human. These 4 criteria are: 
 
1. Mouse lncRNA was induced by TGFβ  >2-fold in NMuMG by follow up RT-
qPCR validation. This criterion served to validate the array and eliminate false 
positive data points which may have been introduced during statistical analysis. 
This also confirmed that the mouse lncRNA is regulated by an established 
signaling pathway (TGFβ pathway) and associated transcription factors. Due to 
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the high conservation of lncRNA promoter elements, lncRNAs are more likely to 
be functional if they are regulated by established transcription factors which are 
tightly regulated in the cell. 
2. Mouse lncRNA has significant sequence identity to human. Mouse lncRNA 
sequence was used as query and BLAST analysis (blast.ncbi.nlm.nih.gov/ 
Blast.cgi) was performed against human genome (all assemblies) with a “semi-
discontiguous” cutoff. The BLAST was against the genome because using this 
strategy we were likely going to identify novel regions within the human DNA that 
contained sequence similarity, however did not contain an annotated gene. 
Currently, there are only about 3,991 lncRNAs annotated in NCBI database [148]. 
Also, a “semi-discontiguous” cutoff was used because it was unlikely there would 
be exact sequence identity across the entire length of the gene, but rather many 
short or some long stretches of high complementarity. In relation to the query, we 
refer to the length of the stretch as “coverage”, and the amount of sequence 
similarity as “identity”. 
3. The BLAST query must locate at syntenic loci in human genome. Strong 
sequence coverage and identity that also locates at syntenic loci in human 
genomes provide strong evidence that this lncRNA has been retained through 
selective pressures of evolution. It is also important to check if this same 
sequence identity locates at syntenic loci across species, this will further support 
the argument for evolutionary conservation. If the BLAST sequence does not 
map to syntenic loci, this could be due to redundancies and repeat elements 
within the genome that may be transposable elements. Although these regions 
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(i.e. Alu repeats and SINEs) may be functional in their own right, this study 
focuses to characterize lncRNA genes and not transposable elements. 
4. Mouse lncRNA and identified genomic location in human can not overlap 
with a protein coding gene. This is to eliminate doubt that this lncRNA is not 
actually a conserved region within a protein coding gene; i.e. exonic, intronic, and 
untranslated regions (UTRs). Proteins retain high sequence similarity across 
species. It is important that the mouse and putative human ortholog are free 
standing and intergenic, to eliminate any doubt that lncRNA is associated with a 
protein coding transcript. There are examples of functional antisense and sense 
lncRNAs that reside within and overlap with protein coding mRNAs, however 
these were not considered in this study. 
 
Test for expression of predicted human ortholog transcript. We have 
selected the top 200 TGFβ-induced mouse lncRNAs identified in microarray to be 
further analyzed using the 4 criteria described above. Using this strategy only 10 of the 
200 mouse lncRNAs met all 4 criteria. Using the largest stretch of known conserved 
sequence region in human, real-time PCR (RT-qPCR) primers were designed within this 
region to detect presence of a transcript in human cells and its regulation by TGFβ. To 
test this, we treated the primary human mammary epithelial cell, HMEC, with vehicle or 
TGFβ for 24 hours and performed RT-qPCR. The aim of this strategy would be to 
predict orthologs that are co-regulated by TGFβ in mouse and human, and provide an 
avenue to demonstrate primers designed were on target. We can further validate this 
through use of siRNAs. 
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Figure 10. Dysregulated mRNAs in TGFβ-induced EMT.   (A) Scatter plot analysis 
comparing all mRNA changes vehicle vs. TGFβ-treated NMuMG cells (red and green 
dots represent up-regulated and down-regulated mRNAs, respectively).  (B) Diagram 
summarizing number genes changed.  (C & D) Real-time PCR analysis of 
representative TGFβ down-regulated (C) and up-regulated (D) mRNAs.  Asterisks 
represent p<0.05. 
 
The stretches of similarity (“coverage”) typically ranged from ~100nt to 1kb, and 
therefore designing RT-qPCR primers for a 100-150 base amplicon was not a problem. 
It is also important to note that all samples were DNase treated prior to reverse 
transcription step to eliminate genomic contamination and signal during PCR step. 
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Interestingly, we observed that 3 of the 10 predicted human lncRNA orthologs were also 
induced greater than 2-fold by TGFβ in HMEC (Fig 12A). 
 
 
 
Figure 11. Schematic representation and workflow for identifying conserved 
human orthologs. Each significantly up-regulated lncRNA in microarray was subjected 
to 4 criteria. If all criteria were met, RTqPCR primers were designed for human lncRNA 
to check changes in expression in TGFβ-treated HMEC cells. 
 
  
The 3 mouse lncRNAs that have a human ortholog also regulated by TGFβ are 
AK578, BB049, and AK060.  Interestingly, BB049 maps to annotated human lncRNA 
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WDFY3-AS2. In addition, although human ortholog of AK562 was not induced greater 
than 2-fold by TGFβ in HMEC, we were still interested in this transcript given its 
genomic location within the 5-prime distal region of the HOXA locus. Several conserved 
and functional lncRNAs have been shown to reside in HOX gene clusters, and therefore 
we did not want to rule out the possibility that a functional lncRNA locates at this 
location [48, 149, 150]. We next checked several established breast cancer cell lines for 
expression of each of the 4 conserved lncRNAs. Interestingly, all 4 human orthologs 
were over expressed in human breast cancer cell lines by RT-qPCR in comparison to 
HMEC control, and each had a unique expression pattern (Fig 12B). 
 
Human AK578 is over-expressed in human breast cancer patient. To provide 
a proof of concept for how we settled on these 4 candidates, we will retrospectively 
discuss AK578. Given the fact that if mouse AK578 is (1) regulated by TGFβ, (2) shares 
significant sequence identity with human, (3) maps to syntenic loci, and (4) this region 
does not overlap with any protein coding genes, we hypothesized that there was a 
strong chance a human ortholog existed. 
Mouse AK578 is ~2.8 kb transcript that locates on mouse chromosome 13 and 
resides in an intergenic region with no overlap with protein coding genes. AK578 was 
BLAST-ed to the human genome on “semi-discontiguous” cutoff, and this showed that 
human genome contains a conserved region at syntenic loci in chromosome 5q14 (Fig 
13A). This region of the genome is conserved in human with 68% “coverage” and 85% 
“identity” to mouse AK578. This genomic region, to varying degrees, is conserved 
across several other species, including chimpanzee, rat, bull, and even zebrafish (Fig 
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13B), suggesting that this region has been selected through evolutionary pressures and 
contains a functional element. 
 
 
 
Figure 12. Ortholog lncRNAs are regulated by TGFβ and overexpressed in breast 
cancer cell lines. (A) Basal level expression was detected for all 10 predicted orthologs, 
including 3 were regulated by TFGβ in HMEC (*). A fourth ortholog remained of interest 
due to the fact that it’s genomic location in the very well conserved HOXA locus (#). (B) 
All 4 human orthologs show elevated expression across a panel of established breast 
cancer cell lines in comparison to normal cell HMEC. 
 
 
RT-qPCR primers were designed for mouse and human AK578. NMuMG and 
HMEC cells were treated with TGFβ (5 ng/ml) for 24 hours and subsequently assessed 
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for AK578 expression. As indicated in microarray analysis, mouse AK578 was validated 
as being induced by TGFβ  >2.5-fold. Interestingly, we were able to detect ~3-fold 
induction of a human ortholog when using qPCR primers designed within conserved 
human region (Fig 13C). These data suggest that a conserved human transcript 
regulated by TGFβ does exist and our strategy was successful. We also obtained 
human patient breast normal and tumor RNAs from Moffitt Cancer Center Tissue Core 
to assess expression of human AK578. We performed semi-quantitative qPCR (semi-
qPCR) and observed significant elevated expression of AK578 in patient breast tumor 
(T) compared to normal control (N) RNA samples (Fig 13D). This result suggests that 
AK578 expression is relevant in human and may functionally contribute to breast cancer 
development and metastasis. 
The following chapters will discuss functional characterization and mechanisms 
of the other 3 mouse and human ortholog candidates AK562, BB049, and AK060. 
 
Methods 
 
LncRNA Microarray. NCode™ Mouse Noncoding Microarray chip from Life 
Technologies (Carlsbad, CA, USA), which contains 10,802 lncRNAs and 25,178 
protein-coding genes, was used to interrogate lncRNA and mRNA changes in vehicle- 
versus TGFβ-treated (5 ng/ml) NMuMG cells after 24 hours. TGFβ was purchased from 
R&D Systems (Minneapolis, MN, USA). Total RNA was end labeled, and hybridized to 
the array. Hybridization and analysis were performed in MicroArray Core at H. Lee 
Moffitt Cancer Center. 
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RNA isolation and RT- and semi- qPCR polymerase chain reaction. Total 
RNAs were isolated with Trizol reagent following manufacturer’s protocol (Life 
Technologies and then subjected to RT reaction using High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Carlsbad, CA, USA). The RT product was used for 
subsequent qPCR.  The qPCR was performed with SYBR Green 2x Master Mix (Life 
Technologies Carlsbad, CA, USA) on ABI HT9600 from Applied Biosystems (Foster City, 
CA, USA) and the data were collected and analyzed using ABI SDS version 2.3. ∆CTs 
were normalized to GAPDH, and ∆∆CT analysis was performed to calculate relative 
RNA expression. 
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Figure 13. Mouse AK578 has human ortholog transcript and is up-regulated in 
patient breast tumor. (A) Mouse AK578 and AK578 (h) locate at syntenic loci are 
intergenic sharing no overlap with protein coding gene. (B) Mouse AK578 is very well 
conserved across several species in sequence identity and coverage including 
zebrafish (Danio rerio). (C) AK578 (h) has elevated expression in 16 human breast 
tumor RNAs examined in comparison to 8 normal breast controls. 
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Table 3. Top up-regulated lncRNAs following TGFβ-induced EMT in NMuMG. 
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Table 4. Top down-regulated lncRNAs in TGFβ-induced EMT in NMuMG. 
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CHAPTER 3 
LncRNA-HIT mediates TGFβ-induced EMT in mammary epithelia and associates 
with metastasis and poorer overall patient survival 
 
Introduction 
  
The Homeobox genes (Hox genes) are well-conserved across several species 
and encode for a cluster of transcription factors important in development [151]. In 
mouse, human, and other vertabrates, the Hox genes are organized into 4 groups; 
Hoxa, Hoxb, Hoxc, and Hoxd. These genes are spatially and temporally expressed 
during embryogenesis and development to ensure proper segmentation and bilateral 
symmetry across the body axis [152]. For this reason, the expression of the Hox genes 
is very tightly regulated by several factors, as disruption can result in major 
developmental complications [153]. It has now become apparent that in malignancies 
such as cancer, Hox genes can become dysregulated and drive tumorigenesis and 
metastasis. It has also been suggested that Hox gene expression is partly governed by 
locally residing lncRNAs that can act in “cis” or in “trans” [48, 149]. 
In this Chapter, we identified mouse AK562 to be an uncharacterized lncRNA 
which is located in Hoxa gene cluster and significantly up-regulated in the lncRNA 
microarray. AK562 resides downstream in the sense direction but not overlapping with 
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Hoxa13 that was significantly Induced by TGFβ, and thus was named lncRNA-HIT.  
Depletion of lncRNA-HIT inhibits TGFβ induced migration, invasion, and EMT in both 
NMuMG and 4T1 cells.  LncRNA-HIT is well conserved in sequence and chromosomal 
location from mouse to human. We were able to detect lncRNA-HIT in human and 
observed that increased expression directly correlates with breast cancer progression. 
Furthermore, we showed that human lncRNA-HIT can drive breast cancer by positively 
regulating HOXA13. The following discusses mouse and human ortholog, lncRNA-HIT. 
 
Results 
      
LncRNA-HIT mediates TGFβ-induced invasion, migration, and EMT in 
NMuMG cell. LncRNA-HIT is one of the top TGFβ up-regulated lncRNAs, and was of 
particular interest to us given its genomic location i.e., within the homeobox domain A 
(HOXA) gene cluster.  LncRNA-HIT resides in the sense orientation to the HOXA 
protein genes and downstream of HOXA13. There is no overlap between these 
transcripts and a gap of ~1.4 kb between the HOXA13 3-prime termini and lncRNA-HIT 
5-prime transcriptional start site (Fig 14A). Previous studies have shown that the HOX 
gene clusters (HOXA, HOXB, HOXC, and HOXD) are very well conserved across 
species and several lncRNAs have been shown to be functionally important within these 
regions [48, 149, 150].   
          Consistent with the microarray finding, RT-qPCR analysis showed that lncRNA-
HIT expression was induced by TGFβ (Fig 14B).  LncRNAs have been shown to play 
functional roles in both the nuclear and cytoplasmic compartments [56, 154-156]. 
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Therefore, we performed cellular fractionation after 24 hours of treatment with TGFβ to 
assess the subcellular localization of lncRNA-HIT. We observed that lncRNA-HIT 
expression was induced and localized to the nucleus upon TGFβ treatment (Fig 14C), 
suggesting that lncRNA-HIT functions in the nucleus. 
 
 
 
 
Figure 14. LncRNA-HIT locates in Hoxa gene cluster and is induced by TGFβ . (A) 
Diagram shows lncRNA-HIT location. (B) RT-qPCR revealed that lncRNA-HIT is 
induced in NMuMG cells after TGFβ treatment for 24 hours. (C) lncRNA-HIT is 
predominantly localized in the nucleus. Following treatment with vehicle or TGFβ for 24 
hours, NMuMG cells were fractionated and then subjected to semi-quantitative PCR 
(top), and semi-quantitative PCR with control primers (medium and bottom).  
 
 
LncRNA-HIT mediates TGFβ-induced motility and EMT. We further designed 
2 siRNAs against lncRNA-HIT (si-HIT-1 and si-HIT-2) to experimentally address its 
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functional significance in TGFβ-induced migration, invasion and EMT. NMuMG cells 
were transfected with scrambled control siRNA (si-CTL), si-HIT-1, or si-HIT-2 for 48 
hours. Cells were then treated with TGFβ (5 ng/ml) or vehicle control for 24 hours.  
Following confirmation of knockdown of lncRNA-HIT (Fig 15A), we performed two-
chamber migration and invasion assays and found that depletion of lncRNA-HIT 
significantly inhibited TGFβ-induced migration and invasion compared to si-CTL (Fig 
15B-C). 
TGFβ-induced EMT in NMuMG causes the cell to move from an epithelial to a 
more mesenchymal and fibroblast-like gene signature. A hallmark of EMT is the loss of 
E-cadherin and increase of Vimentin expression. To test whether depletion of lncRNA-
HIT can abrogate TGFβ-induced EMT, we transfected the cells for 48 h with si-CTL, si-
HIT-1, and si-HIT-2 and then treated cells with and without TGFβ for 24 h to induce 
EMT.  Immunoblotting analysis revealed that TGFβ treatment reduced E-cadherin and 
increased Vimentin in si-CTL cells.  However, knockdown of lncRNA-HIT largely 
overrode TGFβ action in E-cadherin and Vimentin expression (Fig 15D). This result was 
recapitulated using immunofluorescence staining to visualize expression of E-cadherin 
and Vimentin (Fig 15E).  We noted that TGFβ-disrupted tight junctions were largely 
restored by knockdown of lncRNA-HIT. 
  
Ectopic expression lncRNA-HIT increases cell motility and EMT. Moreover, 
we examined the effects of overexpression of lncRNA-HIT alone on EMT in NMuMG 
cells.  Following transfection of lncRNA-HIT into NMuMG cells (Fig 16A), we observed a 
significant increase in both migration and invasion (Fig 16B-C). Ectopic 
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Figure 15. LncRNA-HIT mediates TGFβ-induced cell migration, invasion and EMT. 
(A) NMuMG cells were transfected with indicated siRNAs.  After treatment with vehicle 
or TGFβ for 48 hours, RNAs were isolated and analyzed for lncRNA-HIT expression 
using real-time PCR.  (B-C) Depletion of lncRNA-HIT reduces TGFβ-triggered cell 
migration and invasion.  LncRNA-HIT knockdown and control NMuMG cells were 
seeded in Boyden chamber without (B) and with (C) matrigel to assess changes in 
migration and invasion. (D-E) Knockdown of lncRNA-HIT abrogates a hallmark change 
of EMT induced by TGFβ.  NMuMG cells were transfected with indicated siRNAs.  After 
48 hours of transfection, the cells were left untreated or treated with TGFβ for 16 hours. 
Expression of E-cadherin and Vimentin were assessed by Western blot (D). 
Immunofluorescence staining was also performed with antibodies against E-cadherin 
and Vimentin (E).  Note: TGFβ-induced tight-junction dissolution was largely rescued by 
depletion of lncRNA-HIT.  Asterisks represent p<0.05. 
 
 
expression of lncRNA-HIT was also able to disrupt tight junction as indicated by E-
cadherin immunofluorescence staining (Fig 16D). Collectively, these data indicate that 
lncRNA-HIT plays a pivotal role in TGFβ-induced cell migration, invasion, and EMT. 
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Figure 16. Over-expression of lncRNA-HIT promotes migration, invasion and 
disrupts tight junction. (A) LncRNA-HIT was ectopically expressed in NMuMG cells 
for 48 hours. Cells were then seeded in the upper Boyden Chamber without (B) and 
with (C) matrigel to determine changes in migration and invasion. (D) Presence of tight 
junction following overexpression of lncRNA-HIT was assessed using E-cadherin 
antibody for immunofluorescence staining. 
  
 LncRNA-HIT is up-regulated in 4T1 cells and its depletion inhibits cell 
migration, invasion, lung metastasis and tumor growth. We further examined 
lncRNA-HIT expression in four well-characterized mouse mammary tumor cell lines 
(67NR, 168FARN, 4TO7 and 4T1) derived from a single spontaneously arising 
mammary tumor in a BALB/c mouse. Although each of these tumor cell lines is able to 
form primary tumors, they have different metastatic properties. 67NR cells form primary 
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tumors readily, but tumor cells do not intravasate. 168FARN cells can be detected in 
lymph nodes but rarely in other tissues, suggesting that they can enter the vasculature, 
but extravasate inefficiently. 4TO7 cells can disseminate from primary mammary tumors 
into the lungs but don't form visible lung nodules. Moreover, disseminated 4TO7 cells in 
the lungs rapidly disappear when the primary tumor is removed, suggesting that they 
are unable to colonize in distant sites. 4T1 cells are fully metastatic and form 
macroscopic lung nodules from primary mammary tumors.  Interestingly, lncRNA-HIT 
was significantly elevated in the 4T1 cell and expressed at low levels in other 3 cell lines 
(Fig 17A), suggesting that lncRNA-HIT may be involved in breast cancer metastasis.  
The importance of lncRNA-HIT in 4T1 cell migration and invasion was further 
investigated.  After cells were transfected with si-HIT-1, and si-HIT-2 as well as si-CTL 
for 48 h (Fig 17B), two-chamber migration and invasion assays were performed as 
described above.  After 16 hours, we observed a significant reduction in both migration 
and invasion of 4T1 cells in which lncRNA-HIT was depleted (Fig 17C-D). However, we 
did not observe that TGFβ induced lncRNA-HIT in 4T1 cells and that knockdown of 
lncRNA-HIT had no effect on TGFβ-induced 4T1 cell migration and invasion (data not 
shown).  
We next examined the effect of lncRNA-HIT on anchorage independent growth in 
soft agar following depletion of lncRNA-HIT. Compared to si-CTL treated 4T1 cells, si-
HIT-1 and -2 transfected cells resuspended in soft agar and cultured for 2 weeks 
showed markedly reduced colony formation capacity (Fig 17E). Notably, the orthotopic 
breast cancer model revealed that knockdown of lncRNA-HIT dramatically inhibited 
number of metastatic lung nodules, breast tumor volume, and tumor weight (Fig 17F-H). 
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Identification of E-cadherin as a major target of lncRNA-HIT. To identify the 
genes regulated by lncRNA-HIT, we performed Affymetrix gene expression analysis 
after 48 h ectopic expression of lncRNA-HIT in NMuMG (Fig 18A). One of the significant 
deregulated genes that are associated with EMT was E-cadherin.  Accumulating studies 
have shown that loss of E-cadherin is not only a hallmark of EMT but also a key driver 
of EMT and metastasis [157-160].   Thus, we further examined if lncRNA-HIT inhibits E-
cadherin transcription by performing RT-qPCR and using E-cadherin luciferase 
promoter assay. Following ectopic expression of lncRNA-HIT, we observed a significant 
loss of E-cadherin mRNA and promoter activity (Fig 18B-C). Furthermore, this 
correlated with a loss of E-cadherin protein after 72 h overexpression of lncRNA-HIT 
(Fig 5D), however we did not see changes of other EMT-associated genes ZEB1 or 
Snail at this time point. Further, the effects of lncRNA-HIT induced EMT, migration, and 
invasion were rescued through introduction of ectopic E-cadherin (Fig 18E-G). 
 
LncRNA-HIT is conserved across several species. In “BLAST-ing” mouse 
lncRNA-HIT to the human genome, we found a significant conservation at syntenic 
locus in human chromosome 7p15 located downstream of HOXA13 in sense direction 
(Fig 19A), suggesting that lncRNA-HIT was retained through evolutionary pressures. 
The conservation from mouse to human genomic sequence is 79% identity across 99% 
coverage. Interestingly, lncRNA-HIT is well conserved in several other higher organisms 
at the DNA level. (Fig 19B). Furthermore, to check for evidence and expression at the 
RNA level in human, we “BLAST-ed” the human genomic DNA sequence to the 
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expressed sequence tag bank (ESTs). This result showed several reported transcripts 
residing within this region and thus lncRNA-HIT expression at the RNA level (Fig 19C). 
 
 
Figure 17.  LncRNA-HIT is elevated in metastatic 4T1 cells and its knockdown 
results in significant reduction of cell migration, invasion, and metastasis. (A) 
Expression of lncRNA-HIT was evaluated in 4 isogenic mouse breast cancer cell lines 
67NR, 168FARN, 4T07 and 4T1 by semi-quantitative RT-PCR. (B) Knockdown of 
lncRNA-HIT with 2 siRNAs in 4T1 cells.  Cells were transfected with indicated siRNAs 
and then analyzed lncRNA-HIT expression by RT-qPCR.  (C and D) Depletion of 
lncRNA-HIT dramatically reduces 4T1 cell migration and invasion.  Following treatment 
with indicated siRNAs, 4T1 cells were assayed for cell migration and invasion.  (E) Soft 
agar colony formation assay was performed after 4T1 cells were transfected with si-CTL, 
si-HIT-1, or si-HIT-2. Colony forming capactity was dramatically decreased after 2 
weeks in lncRNA-HIT depleted cells. (F) Orthotopic breast cancer model.  Control and 
lncRNA-HIT knockdown 4T1 cells (4 x 106) were injected to mammary fat pad of female 
nude mice and tumor growth was monitored for 4 weeks.  Number of metastatic lung 
nodules (F), tumor volume (G), and tumor weight (H) were assessed at completion of 
experiment.   Asterisks represent p<0.05. 
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Figure 18. E-cadherin is a target of lncRNA-HIT. (A) Affymetrix Gene Expression 
Analysis was performed on NMuMG cells transfected with vector and lncRNA-HIT. (B) 
RT-qPCR was performed to confirm a loss of E-cadherin expression. (C) PGL3-E-
cadherin promoter was co-transfected with vector or lncRNA-HIT into NMuMG cell for 
48 hours and assayed for luciferase activity. (D) After 72 h overexpression of lncRNA-
HIT, expression of E-cadherin, ZEB1 and Snail were examined by immunoblot with 
indicated antibodies. (E-G) After 72 hours transfection, ectopic expression of E-cadherin 
was able to rescue lncRNA-HIT effects on loss of tight junction (E), migration (F) and 
invasion (G). Asterisks represent p<0.05 
 
 LncRNA-HIT is elevated in human breast cancer cell lines and knockdown 
reduces migration and invasion. Since we observed that lncRNA-HIT is conserved in 
human genome and several ESTs reside in this location, we designed PCR primers and 
siRNAs within this region to test for expression and knockdown. We performed semi- 
  
 64 
 
 
Figure 19. LncRNA-HIT is conserved in across several species and human ESTs 
have been reported. (A) Mouse lncRNA-HIT was “BLAST-ed” to human genomic DNA, 
and results show significant similarity and coverage at snytenic loci in human 
chromosome 7p15. (B) LncRNA-HIT is well conserved in several species at genomic 
DNA level. (C) In “BLAST-ing” human genomic sequence corresponding to lncRNA-HIT 
to the EST database, several RNA transcripts have been reported in this location. 
  
quantitative PCR (semi-qPCR) in a panel of established breast cancer cell lines and 
observed up-regulation of lncRNA-HIT in several including MD-AMB-231, HS578T, 
BT474, MD-AMB-361, and T47D (Fig 20A).  In the highly metastatic MD-AMB-231 we 
were able to knockdown lncRNA-HIT to 0.32-fold and 0.39-fold expression respectively 
using si-hHIT-1 and si-hHIT-2 in comparison to control siRNA (si-CTL) (Fig 20B). After 
knockdown of lncRNA-HIT for 48 h, cells were seeded in upper Boyden Chambers and 
assayed for changes in migration and invasion (matrigel coated). Both si-hHIT-1 and -2 
resulted in significantly reduced migration and invasion after 16 h (Fig 20C-D). 
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Depletion of lncRNA-HIT decreases primary tumor growth and metastasis 
in vivo. Given that we were able to reduce 4T1 cell tumor growth and lung metastasis 
(Figure 17) and human breast cancer cell migration and invasion in vitro setting (Figure 
20), we next investigated whether knockdown of lncRNA-HIT could reduce cancer 
phenotypes in vivo in human breast cancer cells. To do this, we employed a mouse 
orthotopic xenograft model using stable expressing luciferase MD-AMB-231 in 
 
 
 
Figure 20. Human lncRNA-HIT is over-expressed in several breast cancer cells 
lines and depletion of lncRNA-HIT results in reduced migration and invasion. (A) 
Semi-qPCR was performed in a panel of breast cancer cell lines for expression of 
lncRNA-HIT. (B) Knockdown of lncRNA-HIT was confirmed by RT-qPCR in MD-AMB-
231. After 48 h post-knockdown, cells were assayed for migration (C) and invasion (D). 
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NOD/Scid gamma (NSG) mice. NSG mice are advantageous in orthotopic cancer 
models due to germline SCID mutation in the Prkdc gene and an additional targeted 
mutation in the IL2RG gene (IL2 receptor) [161, 162]. The Prkdc mutation results in 
mutation of DNA-PK gene product that can no longer function in DNA repair process. 
This results in B and T lymphocytes being able to successfully undergo V-D-J 
recombination and therefore can not express function B and T receptors. The IL2 
receptor is critical for natural killer cell (NKT) function and this mutation will disrupt the 
ability of IL2R to recognize the IL2 ligand. Therefore, the NSG mice have no adaptive 
immunity and a severely impaired innate immunity. These deficiencies allow for 
reproducible xenografts of human cancer cells, as well as more reliable metastasis 
models including breast cancer [163]. 
MD-AMB-231-Luciferase cells were transfected with si-CTL or si-HIT-1 for 48 
hours and then washed in PBS and trypsinized. Cells were then spun at low speed and 
resuspended in PBS at a concentration of 4 x 106 cells per 100 ul. Four NSG mice from 
each group received injection in the lower mammary fat pad. Tumors were established 
and tracked over the course of 7 weeks. Similar to mouse 4T1 cells, knockdown of 
lncRNA-HIT in MDA-MB-231 had significantly slowed tumor growth and volume (mm3) 
as measured by standard caliper measurements and as quantified by luciferase activity 
using Xenogen Bioluminescent Imaging System and Software (Fig 21A-C). At the 
endpoint week 7, there was also significantly more decreased luciferase activity in the 
lung in lncRNA-HIT knockdown cell compared to si-CTL (Fig 21D-E). Further, 
hematoxylin and eosin (H & E) staining revealed less lung nodules in si-HIT group (Fig 
21F). 
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LncRNA-HIT regulates 5-prime distal HOXA genes including HOXA13. A 
previous report has shown that HOTTIP, a distal 5-prime residing lncRNA, can 
positively regulate locally residing genes like HOXA13 and HOXA11 through recruitment 
of the WDR5/MLL1 chromatin remodeling complex [149]. Since lncRNA-HIT also 
resides in this region we hypothesized that it also may regulate genes within HOXA 
cluster. To test this, we transfected MD-AMB-231 cell line with si-CTL and si-HIT-1 for 
 
 
Figure 21. NSG mouse orthotopic model of control versus depleted lncRNA-HIT. 
(A-C) MD-AMB-231-Luciferase cells were transfected with control (si-CTL) or si-HIT-1 
for 48 h, washed, trypsinized, and 4 x 106 cells were injected into lower fat pad at day 0. 
Tumor volume (mm3) was tracked and quantified via standard caliper measurements 
(A) and bioluminescent imaging (B & C). Image is representative of primary tumor at 
week 3 post injection. (D-E) Just prior to sacrificing, lungs were imaged and quantified 
for luciferase activity. (F) After sacrificing lungs were removed, paraffin embedded, and 
H & E stained to visualize metastasis. Asterisks represents p<0.05. 
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48 h, isolated total RNA, and performed RT-qPCR for expression of genes in this cluster. 
Interestingly we found a similar pattern in that depletion of lncRNA-HIT resulted in 
decreased RNA expression of HOTTIP, HOXA13, and HOXA11 (Fig 22A). However we 
observed no significant change in HOXA10, HOXA9, and HOXA7. This suggests 
lncRNA-HIT is “cis” acting and can positively regulate genes in close proximity. The loss 
of HOXA13 was also evident at the protein level (Fig 22B). 
 
 
 
 
Figure 22 LncRNA-HIT knockdown results in decreased mRNA expression 
neighboring genes. (A) MD-AMB-231 was transfected with si-CTL or si-hHIT-1 for 48 h, 
total RNA was isolated. RT-qPCR analysis was performed on a panel of genes within 
HOXA locus. (B) Similarly transfected cell were lysed and assayed for HOXA13 
expression. Asterisks represents p<0.05. 
 
 
HOXA13 is important in driving breast cancer migration and invasion. It has 
previously been reported that HOXA13 can be cancer promoting and indicator of poorer 
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patient survival in esophageal squamous carcinoma and hepatocellular carcinoma [164, 
165]. Since lncRNA-HIT regulates HOXA13 mRNA and protein, we aimed to assess if 
phenotypic changes are associated with loss of HOXA13 gene product. We transfected 
MD-AMB-231 cells with siRNA against HOXA13 (si-HOXA13). We observed almost 
complete loss of mRNA as measured by semi-qPCR after 48 h knockdown (Figure 23A). 
MD-AMB-231 is a triple-negative highly metastatic cell line that phenotypically looks 
very mesenchymal-like. Interestingly, MD-AMB-231 cells transfected with si-HOXA13 
seem to dramatically revert a more rounded, epithelial-like cell shape and state (Figure 
23B). The significance of this phenotypic change at the molecular level warrants further 
research. Loss of HOXA13 also resulted in significantly impaired migration and invasion 
(Figure 23C and 23D). 
 
LncRNA-HIT is elevated in patient invasive ductal carcinoma, high grade 
tumor, positive lymph node, and associates with poorer patient survival. We 
asked if the expression of lncRNA-HIT associated with cancer invasiveness in human 
primary breast carcinoma.  A total of 89 breast cancer specimens (15 noninvasive and 
74 invasive breast carcinomas) and 4 normal and 9 hyperplasia breast tissue samples 
were examined for the expression of lncRNA-HIT. Locked nucleic acid in situ 
hybridization (LNA-ISH) analyses revealed high levels of lncRNA-HIT in 29 of 74 
invasive tumors but in only 2 of 15 noninvasive cancer tissues (Fig 24A). The level of 
expression of lncRNA-HIT in normal breast tissue was low and gradually increased to 
invasive carcinoma, suggesting lncRNA-HIT may play a role in breast tumor 
progression (Fig 24B). These data further support the findings demonstrating the 
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involvement of lncRNA-HIT in EMT and invasion as we previously observed in NMuMG 
and 4T1 cells, and suggest that conserved human lncRNA-HIT could play a pivotal role 
in breast cancer metastasis. 
 
 
Figure 23. HOXA13 depletion changes cell morphology and results in decreased 
migration and invasion. (A) MD-AMB-231 cells were transfected with si-CTL or si-
HOXA13 for 48 hours and mRNA changes were measured by semi-qPCR. (B) 
Depleting HOXA13 results in a change in MD-AMB-231 cell morphology from a 
mesenchymal-like to a more epithelial-like state. Loss of HOXA13 also resulted in 
decreased cell migration (C) and invasion (D). Asterisks represents p<0.05. 
 
 
 We performed additional TMA-ISH to evaluate if there is clinical or pathological 
relevance in patients with higher expression of lncRNA-HIT. Indeed, elevated levels of 
lncRNA-HIT correlated with poorly differentiated late-grade breast tumor (p = 0.0036)  
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Figure 24. Elevated levels of lncRNA-HIT associates with invasive breast cancer 
in human, late grade tumor, positive lymph node, and poorer overall patient 
survival.  (A) Locked nucleic acid in situ hybridization (LNA-ISH). LNA-oligonucleotide 
of lncRNA-HIT was labeled with digoxigenin-ddUTP using the Dig-5’-end labeling kit 
and hybridized to a human breast cancer TMA. Signal was measured using Allred Scale. 
(B)  Representative photomicrographs of sections of a normal, hyperplasia, non-
invasive and invasive breast tumor tissues are shown.  (C and D) Summary of clinical 
and pathological characteristics associated with elevated lncRNA-HIT expression. (D) 
Kaplan-meier curve was plotted to assess overall patient survival in IDC patients with 
high and low expression of lncRNA-HIT. Asterisks represent p<0.05. 
 
and positive lymph node (p < 0.0001) (Fig 24C). It is interesting to note that although not 
significant, high levels of lncRNA-HIT closely associate with triple-negative breast 
cancer subtype as MD-AMB-231 cell line. Of importance, elevated lncRNA-HIT 
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associates with poorer overall patient survival (p = 0.046) (Fig 24D). This result strongly 
suggests that lncRNA-HIT may play a functional role in patient mortality by driving EMT-
associated phenotypes and metastasis in human cancer. 
 
Discussion 
 
Accumulating studies have demonstrated that TGFβ pathway plays a critical role 
in breast cancer metastasis as the roles of several protein coding genes and miRNAs 
have been described in this process [166-169].  In this study, we report lncRNA 
expression signature of TGFβ-induced EMT in mouse mammary gland epithelial 
(NMuMG) cells. Over 600 lncRNAs were significantly up-regulated or down-regulated 
during EMT, respectively.  Further, we showed that lncRNA-HIT, one of top up-
regulated lncRNA, plays an important role in TGFβ-induced EMT, cell migration, and 
invasion.  Depletion of lncRNA-HIT can reverse the process of EMT associated gene 
expression of E-cadherin and vimentin. Furthermore, lncRNA-HIT expression is 
significantly elevated in the highly metastatic cell lines 4T1 and MDA-MB-231.  
Depletion of lncRNA-HIT results in significant reduction of both migration and invasion 
as well as tumor growth and lung metastasis.  LncRNA-HIT is well conserved in 
sequence and genomic location from mouse to human. Human lncRNA-HIT expression 
is associated with more invasive tumor and breast cancer progression.  These findings 
are important for several reasons.  First, this is the first study to provide lncRNA 
expression signature of TGFβ-induced EMT in mouse mammary gland epithelial cells.  
Second, this study established a critical role of a previously uncharacterized lncRNA, 
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lncRNA-HIT, in TGFβ-induced EMT.  Finally, conserved lncRNA-HIT was shown to be 
an important lncRNA in mouse and human breast cancer progression. 
LncRNA-HIT resides in the 5 prime distal HOXA gene cluster in between but not 
overlapping with HOXA13 and HOXA11-AS. This region of the genome is highly 
conserved across several species and several functional lncRNAs have demonstrated 
to be important within the HOXA clusters, including neighboring HOTTIP and HOXA11-
AS [149, 170, 171].  HOTTIP has been shown to positively regulate the protein coding 
genes in close proximity, notable HOXA13, through the recruitment of WDR5, a 
component of the histone methyltransferase protein MLL complex that promotes 
transcriptional activation [149]. It has also recently been reported that elevated levels of 
human HOTTIP and HOXA13 expression associates with disease progression and 
poorer survival in hepatocellular carcinoma. [165].  However, lncRNAs HOTTIP and 
HOXA11-AS were not induced by TGFβ in our microarray analysis, suggesting lncRNA-
HIT has a unique role in TGFβ-induced EMT.   
While microarray analysis revealed expression changes of a number of typical 
TGFβ-regulated protein-coding genes upon TGFβ-induced EMT, the array didn’t show 
altered expression of lncRNA-HIT neighbor genes including HOXA13 and HOXA11.    
Further investigation is warranted to determine the exact mechanism and target genes 
of lncRNA-HIT, as well as its use as a therapeutic target for breast cancer metastasis 
intervention 
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Methods 
 
Plasmids and siRNAs. A 1,178nt insert of lncRNA-HIT was amplified and TA-
cloned into pGEM-T-easy vector from Promega (Madison, WI, USA) using NMuMG 
genomic DNA template. Plasmid containing insert was sequenced, insert was then 
isolated by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-HIT). SiRNAs 
were designed using IDT siRNA Design Software and 2 best siRNAs against lncRNA-
HIT (si-HIT-1 and si-HIT-2) were determined empirically and used for experimentation. 
 
Affymetrix Gene Expression Array. GeneChip Human Genome U133 Plus 2.0 
Array was purchased from Affymetrix (Santa Clara, CA, USA). After 48 hours 
transfection of pcDNA-HIT in NMuMG, total RNA was isolation from samples and 
hybridized to array according to manufacturer’s protocol. Hybridization and analysis was 
performed in MicroArray Core at H. Lee Moffitt Cancer Center.  
 
Invasion and migration assays. NMuMG and 4T1 cell lines were transfected 
with control siRNA (si-CTL), si-HIT-1 or -2.  After transfection for 48 hours, NMuMG 
cells were treated with TGFβ (5ng/ml) or vehicle control for 24 hours and then seeded 
into the upper chamber of Boyden Chambers coated without (migration) and with 
(invasion) Matrigel. Top chambers contained serum-free media while lower chambers 
had media containing 10% fetal bovine serum. After 16 hours, invasion and migration 
were evaluated and quantified by taking mean and standard deviations of 4 non-biased 
image fields. 
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Cell Lines, treatment, and tumor specimens. Cancer cell lines were obtained 
from ATCC (Manassas, VA, USA) and grown according to recommended culture 
conditions. Primary NMuMG and HMEC cell lines were maintained in Dulbecco’s 
modified Eagle medium plus 10% fetal bovine serum and MEGM medium from Lonza 
Inc. (Hopkinton, MA, USA) plus manufacturer’s supplements, respectively. Cells were 
treated with TGFβ at a concentration of 5 ng/ml for times indicated. Cell transfections 
were performed with Lipofectamine 2000 (Life Technologies) according to 
manufacturer’s protocol. Frozen primary normal and tumor breast tissues were procured 
anonymously from patients who underwent surgery at H. Lee Moffitt Cancer Center, and 
approved by the institutional review board and in accord with an assurance filed with 
and approved by the US Department of health and human services. Each tumor 
contained at least 80% tumor cell as confirmed by microscopic examination. Tissues 
were snap-frozen to avoid RNA degradation and RNA was isolated with Trizol. Breast 
cancer tissue microarray (TMA) was obtained from Moffitt Cancer Center Tissue Core 
and approved under institutional review board. 
 
Immunofluorescence, immunoblotting, and antibodies. The cells were grown 
to 60% confluence on cover slips and transfected with si-CTL, si-HIT-1 or -2 for 48 
hours. Subsequently, TGFβ (5 ng/ml) was added to siRNA transfected cells for times 
indicated in Figure Legends. Briefly, cells were washed with PBS, fixed with 10% 
formalin containing methanol, and permeabilized with 1% NP-40 in PBS. Cells were 
blocked in 10% normal goat serum for 1 hour, and 1:200 dilution of primary antibodies 
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were incubated at 4oC overnight.  Cover slips were washed in PBS 3 times and then 
appropriate secondary antibodies were added at 1:500 dilution. Cover slips were 
washed in TBS 3 times, counterstained with DAPI, and fixed for visualization.  
Western blot was performed as previously described [172]. The band intensity of 
Western blots was quantified using ImageJ Software and represented as ratio of target 
gene/β-actin. Antibody against E-cadherin was purchased from BD Transduction Labs 
(San Jose, CA, USA), Lamin A/C from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA), and antibodies for Vimentin and GAPDH from Cell Signaling Technologies 
(Danvers, MA). Alexa Fluor secondary anti-mouse and anti-rabbit antibodies for 
immunofluorescence were purchased from Life Technologies and HRP linked antibody 
for Western blot analysis was purchased from Sigma (St. Louis, MO, USA). 
 
Soft agar colony formation assay. 4T1 cells were transfected with si-CTL, si-
HIT-1 or -2 for 48 hours then washed, trypsinized, and resuspended in RPMI. A bottom 
layer of 0.6% agar in RPMI was poured, and top layer of 0.3% agar in RPMI was placed 
on top containing 1000 cells per 12-well and allowed to grow for 2 weeks. Four 
replicates were plated for each condition and quantitation is represented as mean and 
standard deviations of colonies counted in 4 non-biased fields. 
 
Luciferase reporter assay. E-cadherin promoter luciferase plasmid was co-
transfected with vector or pcDNA-HIT into NMuMG for 48 hours. Cells were then 
washed in PBS, lysed, and then firefly substrate was added to detect expression of 
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luciferase activity. The reaction was stopped using renilla substrate as a control and 
performed using Promega Dual Luciferase Assay Kit (Madison, WI USA). 
 
Orthotopic mouse breast cancer model. Stable luciferase expressing MD-
AMB-231 cell line was transfected with si-CTL or si-AS2-1 for 48 hours. Cells were 
washed in PBS, trypsinzed, centrifuged, and resuspended in PBS at a concentration of 
4 x 106 cells per 100ul. Six-week old NOD Scid gamma (NSG) mice were purchased 
from Jackson Laboratories (Bar Harbor, ME, USA) and each mouse received 100ul 
injection into lower mammary fat pad. Mice tumor volume and luminescence signal were 
documented by injecting D-Luciferin K+ Salt Bioluminescent Substrate and imaged 
using Xenogen IVIS Imaging System 200 (Waltham, MA, USA). 
 
Locked nucleic acid in situ hybridization of formalin-fixed, paraffin-
embedded tissue microarray (LNA-TMA-ISH). LncRNA-HIT locked nucleic acid (LNA) 
probe was prepared by 5 prime end labeling with digoxigenin-ddUTP terminal 
transferase using the DIG 5 Prime End Labeling Kit from Roche (Indianapolis, IN, USA). 
Following deparaffinization and proteinase K digestion, breast tumor TMAs were 
prehybridized for 1 h and then hybridized with 10 nmol/L LNA lncRNA-HIT probe in a 
hybridization buffer (Roche) for 12 h. After three consecutive washes in 4× SSC/50% 
formamide, 2× SSC, and 0.1× SSC, sections were treated with a blocking buffer 
(Roche) for 1 h and incubated with anti-DIG-AP Fab fragments (Roche) for 12 h. 
Following wash for three times in 1× maleic acid and 0.3% Tween 20 buffer, reactions 
were detected in a detection solution [100 mmol/L Tris-HCl (pH 9.5) and 100 mmol/L 
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NaCl] in the presence of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
from Promega (Madison, WI, USA) and then visualized under a microscope. 
  
 79 
 
 
 
CHAPTER 4 
WDFY3-AS2 promotes breast cancer EMT, metastasis, and associates with poorer 
patient survival and triple-negative breast cancer 
 
Introduction 
 
In the array, we also found mouse lncRNA, BB049, to be up-regulated in 
response to TGFβ treatment. This transcript shares sequence and maps to human 
ortholog, WDFY3-AS2. Interestingly, WDFY3-AS2 expression is also induced by TGFβ 
in the primary human mammary epithelial cell line HMEC. WDFY3-AS2 expression is 
elevated in human breast tumor and metastasis. Clinical and pathological analysis 
revealed that high WDFY3-AS2 associates with poorer patient survival, high grade 
tumor, positive lymph node metastasis, and triple-negative breast cancer subtype. 
Knockdown and over-expression experiments demonstrate that WDFY3-AS2 can 
regulate TGFβ induced EMT, migration, invasion, and proliferation. In vivo, loss of 
WDFY3-AS2 resulted in slowed primary tumor growth and decreased lung metastasis in 
mouse orthotopic xenograft model. Lastly, we have shown that WDFY3-AS2 functions 
in “cis” to regulate WDFY3 and in “trans” to regulate STAT3 through protein binding 
partner hnRNP-R. 
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The WDFY3 gene product, also known as ALFY, is important in selective 
macroautophagy, which can promote clearing of cargo by stimuli other than starvation. 
WDFY3 can interact with the core autophagy promoting machinery, like p62, ATG5, 
ATG12, and LC3 [173]. Interestingly, TGFβ has been shown to selectively activate 
autophagy in human cancers, and in triple-negative breast cancers this can be an 
oncogenic force [174, 175]. STAT3 is a well established oncogenic transcription factor 
that is activated or elevated expression in many tumor types [176]. Hyperactive 
signaling through Janus kinase receptor (JAK) or over-expression of total STAT3 
promotes G1/S transition to drive cell cycle progression and cell proliferation [177]. 
Notably, in triple-negative breast cancers STAT3 can promote autophagic-addiction and 
selective sensitivity to drugs targeting autophagy bafilomycin and chloroquine [178]. 
Given that WDFY3-AS2 regulates both WDFY3 and STAT3 through TGFβ pathway, this 
may provide a novel mechanism for cooperation between pathways in breast cancers. 
This chapter will discuss role of WDFY3-AS2 in further detail. 
 
Results 
 
BB049 and human ortholog WDFY3-AS2 are regulated by TGFβ in 
mammary epithelia. Mouse lncRNA BB049, a 659 base transcript on mouse 
chromosome 5, was another transcript which we predicted to have a human ortholog. 
BLAST analysis showed that BB049 is not only conserved in human (78% identity, 26% 
coverage), but across several species with >75% identity (Figure 25A). Importantly, 
BB049 maps to annotated human lncRNA WDFY3-AS2, providing independent 
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validation that our strategy for discovering human orthologs is effective (Figure 25B). 
Given both BB049 and WDFY3-AS2 are already in NCBI ref seq database, we designed 
primers for RT-qPCR based on these sequences. We confirmed that TGFβ treatment 
significantly induces both mouse and human transcripts greater than 2-fold in NMuMG 
and HMEC, respectively. (Fig 25C-D). 
 
 
Figure 25. BB049 and human ortholog WDFY3-AS2 are regulated by TFGβ in 
mammary epithelia. (A) Using BLAST analysis, BB049 is well conserved across 
several species. (B) BB049 maps to human ortholog lncRNA at chromosome 4q21. (C) 
NMuMG and (D) HMEC were treated with 5ng/ml TGFβ for 24 h and RT-qPCR was 
performed to check expression of BB049 and WDFY3-AS2. Asterisks represents p<0.05. 
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WDFY3-AS2 is elevated in human cancer and associates with lymph node 
metastasis, high grade tumor, triple-negative subtype, and poor patient survival. 
Since WDFY3-AS2 is elevated upon TGFβ-induced EMT in HMEC, we evaluated its 
expression level in human breast cancer. We obtained fresh frozen patient RNA from 16 
normal breast epithelia and 32 primary breast tumor samples from H. Lee Moffitt Cancer 
Center Tissue Core. Semi-qPCR analysis showed that expression of WDFY3-AS2 is 
elevated in breast tumors as compared to normal controls, suggesting that this 
transcript may be functionally relevant in patient (Figure 26A). We next performed TMA-
ISH that was blindly scored by a pathologist based on 2 criteria, percentage of positive 
cells and staining intensity. The breast TMA is composed of cores of normal epithelia, 
DCIS, IDC, and metastasis. We observed significant elevated expression of WDFY3-
AS2 in DCIS, IDC and metastatic lymph node as compared to normal (Figure 26B). 
High levels of WDFY3-AS2 were associated with high grade tumor, positive lymph node 
metastasis, and triple-negative subtype (Figure 26C). Furthermore, high expression of 
WDFY3-AS2 correlated with overall poorer patient survival (Figure 26D). Collectively, 
these data suggest that WDFY3-AS2 is involved in breast cancer initiation and 
progression. 
 
WDFY3-AS2 regulates TGFβ-induced EMT in HMEC. HMEC cells treated with 
TGFβ will become more spindle-shaped and elongated, and protein expression levels of 
E-cadherin will decrease, while Vimentin protein expression will increase. Since 
WDFY3-AS2 is induced in response to TGFβ, we hypothesized that WDFY3-AS2 may 
functionally contribute to TGFβ-induced EMT. To test this, we first designed 2 siRNAs 
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Figure 26. WDFY3-AS2 is over-expressed in breast cancer and is associated with 
poor patient survival and triple-negative breast cancer. (A) Semi-RT-qPRC analysis 
of WDFY3-AS2 expression in 16 normal breast epithelia and 32 primary human breast 
tumors. (B) TMA-ISH was performed on breast cancer TMA to assess expression of 
WDFY3-AS2 at various stages of breast lesions. (C) Relation of expression of WDFY-
AS2 with clinical parameters. (D) Overall patient survival was analyzed and represented 
as Kaplan-Meier Curve. 
 
against WDFY3-AS2 (si-AS2-1 and si-AS2-2) and validated knockdown in MD-AMB-231 
cell line which expresses high level of WDFY3-AS2. We next transfected HMEC cell 
using control siRNA (si-CTL) and best scoring si-AS2-1 for 48 h, and then treated cells 
with TGFβ to induce EMT for 24 h. Si-AS2-1 was able to almost completely eliminate 
the induction of WDFY3-AS2 in response to TGFβ treatment (Figure 27A). Compared to 
untreated control (UNT), TGFβ treated samples showed significant loss of E-cadherin 
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and gain of Vimentin protein expression in si-CTL treated cells.  However, both of these 
responses were partially abolished in cells depleted WDFY3-AS2 by si-AS2-1 (Figure 
27B). This result was also reaffirmed using immunofluorescence staining to visualize E-
cadherin and Vimentin expression on the cell surface (Figure 27C). 
 
 
 
 
Figure 27. Knockdown of WDFY3-AS2 inhibits TGFβ  induced EMT. (A) HMEC was 
left untreated (UNT) or transfected with control siRNA (si-CTL) or siRNA against 
WDFY3-AS2 (si-AS2-1) for 48 h, and then treated with TGFβ for 24 h. Total RNA was 
isolated and examined for WDFY3-AS2 expression by RT-qPCR.  Similarly treated cells 
were assessed for characteristic EMT markers, E-cadherin and Vimentin, by Western 
blot (B) and immunofluorescence staining (C). 
 
 
WDFY3-AS2 regulates migration, invasion, proliferation, and cell cycle. 
TGFβ treatment increases cell migration and invasion in HMEC cell line similar to the 
NMuMG cell line. To test WDFY3-AS2’s contributed to this, we pre-treated HMEC cells 
for 24 hours with TGFβ (5 ng/ml) and then transfected si-CTL, si-AS-1, or si-AS2-2 for 
48 hours while still in the presence of TGFβ. After 72 h of this treatment, we noticed a 
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significant loss of WDFY3-AS2 expression using both siRNAs (Figure 28A). We then 
assayed for cell migration and invasion using Boyden chambers. In both cases, TGFβ-
induced migration and invasion were significantly reduced upon depletion of WDFY3-
AS2 in HMEC compared to si-CTL control (Figure 28B and 28C). 
 
 
Figure 28. Knockdown of WDFY3-AS2 inhibits TGFβ-induced migration and 
invasion. (A) HMEC cells were pre-treated for 24 hours with TGFβ (5ng/ml) to induced 
migration and invasion, and then transfected for 48 hours with si-CTL or siRNAs against 
WDFY3-AS2. At 72 hours RNA was isolated and examined for WDFY3-AS2 expression. 
Once knockdown was confirmed, cells were subjected Boyden 2-Chamber Assay 
without matrigel (B) and with matrigel (C) to assess cell migration and invasion, 
respectively. 
 
 We performed similar assays using highly metastatic MD-AMB-231 human cell 
line. In these experiments, we knocked down WDFY3-AS2 for 48 hours, then placed 
cells in top of Boyden chambers in serum free medium, and initiated cell motility using 
10% serum containing media as chemo-attractant in bottom chamber. Again, after 16 
hours we observed that cell migration and invasion were significantly reduced following 
knockdown of WDFY3-AS2 (Figure 29A-B).  MD-AMB-231 cell line was also assayed 
for changes in proliferation after WDFY3-AS2 knockdown by EdU incorporation. Cells 
were seeded in chamber slides at 70% confluence and transfected with si-CTL, si-AS2-
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1, and si-AS2-2 for 48 hours. The mean number of positive proliferating cells was 
calculated by quantifying 4 non-biased fields. Cells treated siRNAs against WDFY3-AS2 
showed significant reduction of percentage of cells with EdU incorporation (Figure 29C). 
To further investigate contribution of WDFY3-AS2 to cell cycle progression in MD-AMB-
231, after 48 hours knockdown we fixed cells in ethanol and stained nuclear DNA with 
propidium iodide (PI). In cells depleted WDY3-AS2, we observed a significant 
accumulation of cells in G1-phase, and a decrease in S-phase and G2-phase 
populations (Figure 29D). These data suggest that WDFY3-AS2 regulates cell 
proliferation, DNA synthesis and G1-S transition. 
Next we wanted to determine if over-expression of ectopic WDFY3-AS2 could 
also have an effect on invasion, proliferation, and cell cycle. We cloned a 759nt cDNA 
into pcDNA3.1 expression vector (pcDNA-AS2). Ectopic expression of pcDNA-AS2 in 
low metastatic MCF7 cells caused an increase in invasion and EdU incorporation 
(Figure 30A-B). We also performed PI staining and cell cycle analysis on MCF7 cells 
over-expressing WDFY3-AS2 for 48 hours. Ectopic expression resulted in an increase 
of both S-phase and G2-phase cells, and a decrease in G1-population (Figure 30C). 
 
Knockdown of WDFY3-AS2 inhibits primary tumor growth and metastasis 
in vivo. We next investigated whether WDFY3-AS2 knockdown resulted in reduced 
motility and proliferation in vivo. To test this, we employed an orthotopic mouse 
xenograft model by injecting 4 x 106 MD-AMB-231-Luciferase cells which had been 
treated with si-CTL and si-AS2-1, into the lower mammary fat pad. Using the NSG mice, 
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primary tumors were detected and established by the end of week 2. The size of the 
primary tumor and the presence of lung metastasis were measured each week via  
 
 
Figure 29. Knockdown of WDFY3-AS2 in MD-AMB-231 reduces migration, 
invasion, proliferation, and G1 accumulation. (A and B) WDFY3-AS2 was knocked 
down using 2 siRNAs in the highly metastatic cell MD-AMB-231 for 48 hours. Migration 
was subsequently assessed by seeding cells in Boyden 2 Chamber without (A) and with 
(B) matrigel.  (C) Cell proliferation was assessed by incubation of cell with thymidine 
nucleoside analogue 5-ethynyl-2´-deoxyuridine (EdU) for one hour. (D) Cell cycle 
analysis was performed using propidium iodine (PI) staining of nuclei and followed flow 
cytometry. Asterisks denotes p<0.05. 
 
 
standard caliper measurement and bioluminescent imaging. The growth and size of the 
primary tumor were significantly less in the mice injected with cells depleted WDFY3-
AS2 at week 5 and throughout endpoint at week 7 (Figure 31A-C). WDFY3-AS2 
knockdown group also had significantly less tumor weight compared to control (Figure 
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31D). At week 7 endpoint, both groups of mice were injected with luciferase substrate 
and lungs were assessed for photon flux signal. There was a dramatic and significantly  
 
 
Figure 30. Ectopic expression of WDFY3-AS2 increases invasion, proliferation, 
and G2-S population. (A and B) pcDNA-AS2 was transfected into low metastatic 
MCF7 cells for 48 hours.  Invasion (A) and proliferation (B) were assayed using Boyden 
chamber and EdU incorporation. (C) Cells were stained with PI to examine change in 
cell cycle. Asterisks represents p<0.05. 
 
more robust signal of luciferase in lungs of control mice compared to mice injected with 
the cells depleted WDFY3-AS2 (Figure 31E). Lungs from each group were paraffin 
embedded, sectioned, and H&E stained. The number of lung metastasis nodules for 
each group was counted across 3 different sections per lung and averaged. There was 
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a significant decrease in number of lung nodules present in WDFY3-AS2-knockdown 
mice as compared to control mice (Figure 31F). 
 
WDFY3-AS2 regulates protein coding gene WDFY3 and STAT3 via ‘cis’ 
‘trans’ mechanism. There are several examples of antisense lncRNAs regulating 
closest neighboring protein coding gene in “cis” and regulating distant genes in “trans” 
[56, 80, 149, 179]. In order to determine which genes are possible targets of WDFY3-
AS2, we performed Affymetrix Chip Gene Expression analysis on si-CTL or si-AS2-1 
transfected MD-AMB-231 cells (Figure 32A). We observed 2 genes, WDFY3 and 
STAT3 to be significantly down-regulated in response to WDFY3-AS2 knockdown. To 
validate this finding, we designed real-time PCR primers for WDFY3 and STAT3 and 
evaluated RNA expression for both after WDFY3-AS2 knockdown compared to control. 
Consistent with the array data, we observed a significant decrease in both WDFY3 and 
STAT3 mRNA levels after depletion of WDFY3-AS2 by semi-qPCR (Figure 32B). 
Furthermore, we also observed a loss in total WDFY3, phospho-STAT3 and total 
STAT3 at 72 hours knockdown of WDFY3-AS2 in MD-AMB-231 cells (Figure 32C). 
Interestingly, if we first deplete cells of endogenous WDFY3-AS2 by siRNA 
treatment, ectopic expression of pcDNA-WDFY3-AS2 construct was able to completely 
rescue mRNA level of WDFY3 and partially rescue STAT3 (Figure 32D and 32E). In 
MCF7 cells, ectopic expression of pcDNA-WDFY3-AS2  increased phosph-STAT3 and 
total STAT3 protein, however this effect was not seen with WDFY3 protein level (Figure 
32F). 
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WDFY3-AS2 and WDFY3 are co-expressed and elevated WDFY3 is also a 
predictor of poorer patient survival. Since WDY3-AS2 positively regulates WDFY3, 
we next assessed the significance of WDFY3 protein expression in human breast 
tumors and then correlated expression of WDFY3 with WDY3-AS2. 
 
 
 
Figure 31.  Knockdown of WDFY3-AS2 significantly inhibits tumor growth and 
metastasis. (A and B) Stable expressing luciferase MD-AMB-231 cells were 
transfected with si-CTL or si-AS2-1 for 48 hours. Cells were washed in PBS, trypsinized, 
resuspended in PBS, and 4 x 106 cells were injected into lower mammary fat pad per 
mouse. Primary tumor growth was tracked by bioluminescent imaging (A) and caliper 
measurement (B).  (C) Quantification of primary tumor size using photon flux 
measurement at week 5.  (D) Tumors were removed from each mice and weighed. 
Average mean and deviation are plotted. (E) At endpoint week 7, lungs metastasis were 
imaged using bioluminescent. (F) Lungs from mice were paraffin embedded, sectioned, 
H&E stained, and number of metastasis were counted and averaged. 
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Immunohistochemical staining the same breast cancer TMAs was performed with 
antibody against WDFY3. In a total of 135 specimens (normal, DCIS, and IDC), we 
observed 43 cases (31.8 %) of low/low expression (WDFY3-AS2/WDFY3), 40 cases 
(29.6 %) high/high expression, 22 cases (16.2 %) high/low expression, and 30 cases 
(22.2 %) low/high expression. Plotting data in a 2 x 2 contingency table statistical 
 
 
Figure 32. WDFY3-AS2 regulates protein coding gene WDFY3 and STAT3. (A) MD-
AMB-231 cells were treated with si-CTL or si-AS2-1 for 48 hours and Affymetrix Gene 
Expression Analysis was performed. WDFY3 and STAT3 mRNA were shown to be 
significantly down-regulated in response to WFY3-AS2 knockdown. (B) Semi qRT-PCR 
analysis of WDFY3 and STAT3 expression. (C) Western blot protein analysis of WDFY3, 
phosho-STAT3, and total STAT3 protein in MD-AMB-231 cells treated with si-AS2-1, si-
AS2-2 and si-CTL. (D and E) WDFY3 and STAT3 mRNAs were rescued with 
introduction of pcDNA-WDFY3-AS2 after knockdown of endogenous WDFY3-AS2. (F) 
Over-expression of pcDNA-WDFY3-AS2 construct induces phospho-STAT3 and total 
STAT3 protein levels. 
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analysis demonstrated a significantly positive correlation between expression WDFY3-
AS2 (RNA) and WDFY3 (protein) in patients with breast cancer (Figure 33A-B).  
 Furthermore, we also observed co-expression of WDFY3-AS2 and WDFY3 
(mRNA) in 15 established breast cancer cell lines as measured by RT-qPCR and 
plotted by linear regression and R-squared analysis (data not shown).  Collectively, 
these data suggest that WDFY3-AS2 positively regulates WDFY3 expression in vivo. 
Since we have shown that WDFY3-AS2 is strongly associated with triple-negative 
subtype and high grade tumor (Figure 26), we used Kaplan Meier Plotter Database for 
independent validation and found that elevated WDFY3 is also a predictor of poorer 
overall survival. In patients stratified for ER-negative, basal subtype, or high grade 
breast cancers, elevated WDFY3 mRNA is a significant predictor of poorer patient 
survival in all 3 cases (Figure 33C-E). Interestingly, elevated WDFY3 mRNA is of no, or 
reverse, prognostic value in patients with ER-positive, luminal A subtype, or low grade 
tumor (data not shown). 
Since WDFY3 and STAT3 are the targets of WDFY3-AS2, we next examined 
their expression in orthotopic mouse breast tumors derived from WDFY3-AS2 
knockdown and si-CTL transfected MDA-MB-231 cells. Immunoblot analysis revealed 
decreased expression of both WDFY3 and STAT3 in WDFY3-AS2 depleted tumors 
(Figure 34A).   Furthermore, immunohistochemical staining and in situ hybridization of 
paraffin embedded sections of xenograft tumor and lungs showed significantly reduction 
of STAT3 and WDFY3 expression in WDFY3-AS2 knockdown breast tumor and lung 
metastases.  In addition, Ki-67 proliferation marker was also significantly reduced in si-
AS2-1 treated group (Figure 34B). 
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WDFY3-AS2 binds to hnRNP-R to regulate WDFY3 and STAT3. In attempt to 
identify a protein binding partner for WDFY3-AS2, RNA immunoprecipitation (RIP) 
assay was performed. “Sense” and “Antisense” orientations of WDFY3-AS2 RNA were 
in vitro transcribed in the presence of biotin-UTP and mixed with 1 mg of MD-AMB-231 
nuclear extract. Ribonucleoprotein (RNP) complexes were immunoprecipitated using 
agarose-streptavidin.   The bound protein was run on an SDS page gel and silver 
stained for analysis (Figure 35A). We observed a unique protein band in the “sense” 
lane just below the 72-kDa protein marker. This band was extracted and submitted for 
protein identification via mass spectrometry. Analysis revealed a significant enrichment 
of hnRNP-R protein as compared to “antisense” gel band extracted at same molecular 
weight.  To confirm this interaction, we transfected hnRNP-R-FLAG construct into 
HEK293T cells for 72 hours and performed RIP assay using biotinylated “sense” and 
“antisense” RNA probes. After immunoprecipitation using streptavidin-agarose, 
immunoblotting for FLAG showed a significant enrichment in sense binding to hnRNP-R 
versus antisense probe (Figure 35B). We performed similar experiments using 1 mg 
nuclear extract isolated from MDA-MB-231 cell line and immunoblotting against 
endogenous hnRNP-R (data not shown). 
Next we performed the reverse experiment to assess binding of endogenous 
WDFY3-AS2 to hnRNP-R.  We transfected either vector or hnRNPR-FLAG into MDA-
MB-231 cells for 72 hours followed by immunoprecipitation using FLAG antibody. Total 
RNA was isolated from the immunoprecipitates. Semi-qPCR and real-time PCR was 
performed to examine endogenous WDFY3-AS2 binding to hnRNP-R. We observed 
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Figure 33. WDFY3-AS2 and WDFY3 are co-expressed in patient and elevated 
WDFY3 predicts poorer patient overall survival. (A) WDFY3-AS2 and WDFY3 were 
stained using LNA-probe and antibody, respectively.  They are significantly co-
expressed. (B) Representative tissue cores demonstrating increased co-expression of 
both WDFY3-AS2 and WDFY3. (C - D) In stratifying patients, WDFY3, like WDFY3-AS2, 
is also a predictor of poorer overall survival in ER-negative (C) basal subtype (D) and 
grade III tumors (E). 
 
 
about an 8-fold increase in bound WDFY3-AS2 transfected with hnRNP-R-FLAG as 
compared to that transfected with vector (Figure 35C). Endogenous hnRNP-R in MDA-
MB-231 and MCF7 cell lines was also evaluated for bound endogenous WDY3-AS2 by 
comparing immunoprecipitations of anti-hnRNPR and anti-GFP. In both cell lines we 
found greater than 2-fold increase in bound WDFY3-AS2 compared to GFP control 
(Figure 35D). 
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Figure 34. Reduced expression of WDFY3 and STAT3 in WDFY3-AS2 knockdown 
orthotopic mouse breast tumor and lung metastatic lesions. (A) Depletion of 
WDFY3-AS2 in MDA-MB-231 xenograft of primary tumor results in decreased 
expression of both WDFY3 and STAT3 protein. (B) Primary tumor and lungs were 
removed, paraffin embedded, and stained with H&E, LNA-WDFY3-AS2 RNA probe, and 
antibodies against WDFY3 and STAT3, as well as Ki-67. 
 
Previously we have shown that knockdown of endogenous WDFY3-AS2 followed 
by introduction of ectopic WDFY3-AS2 can rescue both WDFY3 and STAT3 RNA levels. 
To assess whether hnRNP-R functionally contributes to this process, we performed the 
same rescue experiments and included cells deficient in hnRNP-R. We noticed that in 
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cells depletion of hnRNP-R, we were unable to restore WDFY3 and STAT3 mRNA 
(Figure 35E). This denoted that WDFY3-AS2 promotes WDFY3 and STAT3 expression 
in an hnRNP-R dependent manner. 
 
Discussion 
 
We identified a long non-coding mouse transcript BB179049 to be significantly 
up-regulated in response to TGFβ, which was mapped to syntenic loci and shared 
sequence with human ortholog WDFY3-AS2. We have shown that WDFY3-AS2 is also 
induced by TFGβ in human HMEC cells, and this regulation in mammary epithelia is 
conserved from mouse to human. We observed WDFY3-AS2 to be elevated in several 
breast cancer cell lines and primary breast tumors compared to normal controls. 
Furthermore, WDFY3-AS2 expression directly increases with progression of disease, 
and is most significantly overexpressed in metastatic lesions. WDFY3-AS2 also has 
clinical and pathological significance in that elevated expression of WDFY3-AS2 is a 
predictor of poorer overall survival, as well as associates with last stage and high grade 
tumors as well as triple-negative breast cancer subtype. Depletion of WDFY3-AS2 
slowed the onset of TGFβ mediated EMT program and also inhibited migration, invasion, 
and proliferation. These results were recapitulated in a mouse orthotopic xenograft 
model in that mice deficient in WDFY3-AS2 showed decreased primary tumor growth 
and lung metastasis. 
WDFY3-AS2 is a natural antisense transcript (NAT) located at the 5-prime region 
but not overlapping with protein coding gene WDFY3. Several examples of NATs are 
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emerging in literature and it is becoming more apparent that a large subset of protein 
coding genes may be regulated by these lncRNAs [180-183]. Here we have shown that 
knockdown of WDFY3-AS2 transcript results in loss of WDFY3 transcript and protein. 
 
 
 
Figure 35. WDFY3-AS2 binds to hnRNP-R. (A) RNA-Immunoprecipitation (RIP) was 
performed using biotinylated “sense” and “antisense” probes and 1mg MDA-MB-231 
nuclear extract. Total bound RNA-protein complexes was run on SDS-page gel and 
silver stained. (B) HEK293T cells were transfected with ectopic hnRNP-R-FLAG. After 
48 h of incubation, RIP was performed. Subsequent Western blotting was done using 
anti-FLAG antibody. (C and D) MDA-MB-231 cells were transfected with hnRNP-R-
FLAG. IP was performed after 72 h, total RNA was isolated from IPs and checked for 
endogenous WDFY3-AS2 expression by semi-qPCR (C) and real-time PCR (D). (E) 
Endogenous hnRNP-R was knocked down using siRNA and then co-transfected with 
pcDNA-AS2. WDFY3 and STAT3 mRNAs were assessed by RT-qPCR. 
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The WDFY3 gene encodes for a protein that enhances selective 
macroautophagy through interaction with p62 and the autophagy effector complex 
consisting of Atg5, Atg12, Atg16, and LC3 [173]. Another report has demonstrated that 
autophagy promotes cell invasion and EMT in hepatocellular carcinoma using TGFβ 
pathway as a key regulatory element [184]. Studies have also shown that potent 
inhibitors of autophagy can have therapeutic benefit in specifically in triple-negative 
breast cancer subtype including those driven by STAT3 [175, 178, 185]. For this reason, 
we found it interesting that elevated WDFY3 associates with poorer patient overall 
survival in these ER-negative and basal subtype, but not ER-positive or luminal subtype 
of breast cancer. 
We have also identified STAT3 as a downstream target of WDFY3-AS2. STAT3 
is a well-established oncogene across several human malignancies [186-188]. The 
JAK/STAT signaling pathway has also been shown to be critical for EMT, invasion, and 
metastasis [189, 190]. One report has demonstrated that there is therapeutic benefit 
using metformin to target STAT3 specifically in triple-negative breast cancer [191]. Our 
data suggest that WDFY3-AS2 is a novel route for TGFβ mediated activation of STAT3 
to enhance both proliferation and EMT phenotypes in breast cancer. 
We have identified hnRNP-R to be a protein binding partner of WDFY3-AS2, and 
this interaction functions to regulate WDFY3 expression. It has recently been reported 
that hnRNP-R can facilitate transcription through its interaction with scaffolding 
components Mediator, TBP, and TFIIH, which can then recruit RNA polymerase II [192]. 
Since WDFY3-AS2 lies in the antisense orientation and upstream to the transcriptional 
start site of WDFY3, this may provide a novel mechanism by which lncRNA can recruit 
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RNA polymerase II to the promoter to activate target gene transcription. However, 
further experimentation is required to solidify this claim. 
Taken together, WDFY3-AS2 is a novel target for therapy in triple-negative 
breast cancer. Since we have shown that WDFY3-AS2 is critical for expression of both 
WDFY3 and STAT3, inhibition of WDFY3-AS2 could suppress associated phenotypes 
facilitated through the function of these two genes. WDFY3-AS2 can also serve as a 
novel biomarker for diagnostic and prognostic utility in the clinic. Future studies in this 
area of research are warranted. 
 
Methods 
 
Invasion and migration assays. Briefly, MD-AMB-231 cell were transfected 
with si-CTL, si-AS2-1, and si-AS2-2 for 48 hours. Cells were washed in PBS, trypsinized, 
and seeded in upper chambers without (migration) and with matrigel (invasion). After 16 
hours top chambers were cleared with cotton, and bottom chamber was fixed in crystal 
violet plus 10% methanol. Average mean and standard deviations were calculated from 
4 non-biased fields. 
 
Cell Lines, treatment, and tumor specimens. Cells were obtained from ATCC 
and grown according to recommended conditions. MD-AMB-231 and MCF7 cell lines 
were maintained in RPMI plus 10% fetal bovine serum. Cell transfections were 
performed using Lipofectamine 2000. Frozen RNAs were procured anonymously from 
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patients at H. Lee Moffitt Cancer Center, and approved by the IRB. Tissues were snap-
frozen to avoid degradation and isolated with Trizol. 
 
Locked nucleic acid in situ hybridization of formalin-fixed, paraffin-
embedded tissue microarray (LNA-TMA-ISH). WDFY3-AS2 LNA probe was prepared 
by end labeling with digoxigenin-ddUTP terminal transferase. Following 
deparaffinization and antigen retrieval, TMAs were hybridized with 10 nmol/L LNA 
WDFY3-AS2 probe in a hybridization buffer for 12 hours. After washing 4× SSC/50% 
formamide, 2× SSC, and 0.1× SSC, sections were blocked for 1 hour and incubated 
with anti-DIG-AP Fab fragments. Following washing in 1× maleic acid and 0.3% Tween 
20 buffer, reactions were processed [100 mmol/L Tris-HCl (pH 9.5) and 100 mmol/L 
NaCl] in the presence of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
and then visualized. 
 
Mouse orthotopic breast cancer model. MD-AMB-231-Luciferase cell line was 
transfected with si-CTL or si-AS2-1 for 48 hours. Cells were washed, trypsinzed, and 
resuspended in PBS at a concentration of 4 x 106 cells per 100ul. Six-week old NSG 
mice received 100ul injection into lower fat pad. Tumor volume and luminescence signal 
were documented and imaged using Xenogen IVIS Imaging System 200 . 
 
Affymetrix Gene Expression Array. As described in Chapter 3. Briefly, MDA-
MB-231 cells were transfected with si-CTL or si-AS2-1, total RNA was isolated and 
  
 101 
hybridized to the chip. Analysis was performed by H. Lee Moffitt Cancer Center 
Molecular Genomics Core. 
  
 Immunoblotting Immunofluorescence, and antibodies. Western blotting was 
performed using standard procedures. Antibodies against WDFY3 and total STAT3 was 
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), and phosho-
STAT3 was from Cell Signaling Technologies (Danvers, MA). For immunofluorescence 
staining, HMEC cells were seeded onto glass cover slips and then transfected with 
siRNAs for 48 hours. Media was then supplemented with TGFβ for times indicated in 
figure legend. Cover slips were then washed in PBS and then fixed in 10% cold 
methanol. Cover slips were then permeablized using 1% NP-40 and blocked in 10% 
normal goat serum. Primary antibody incubation was performed overnight at 4 degrees 
and secondary incubation was at room temperature for 1 hour. Cells were then washed 
in TBS, counterstained with DAPI, and fixed with mounting media for visualization. 
 
Plasmids and siRNAs. A 758nt insert of WDFY3-AS2 was amplified and TA-
cloned into pGEM-T-easy vector from Promega (Madison, WI, USA) using T47D cDNA 
library as template. Plasmid containing insert was sequenced, insert was then isolated 
by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-AS2). SiRNAs were 
designed using IDT siRNA Design Software. Two siRNAs against human WDFY3-AS2 
(si-AS2-1 and si-AS2-2) were determined empirically and used for experimentation. 
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RNA immunoprecipitation (RIP) assay. WDFY3-AS2 sense and antisense 
DNA templates were generated using standard PCR and incorporating a T7 RNA 
polymerase II recognition site through the forward primer, respectively. PCR fragments 
were purified and 1ug template was used for in vitro transcription reaction using 
MAXIscript In Vitro Transcription Kit (Life Technologies) in the presence of biotin labeled 
UTP Roche (Branchburg, NJ, USA). Protocol used was previously described. [49] 
Briefly, 3ug in vitro transcribed RNA was incubated with 1mg nuclear extract, 
immunoprecipitated with 60ul streptavidin beads (Life Technologies), and run on a SDS-
page gel. Gel was silver stained, and unique bands in sense lane were submitted for 
protein identification via mass spectrometry.
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CHAPTER 5 
LncRNA TIL involved in breast cancer EMT, metastasis, and cancer cell 
stemness through regulation of NF90/C-MYC 
 
Introduction  
  
 Another mouse lncRNA AK060 was also found to be significantly up-regulated by 
TGFβ in the microarray analysis and predicted to have a human ortholog. We were in 
fact able to detect a conserved lncRNA also regulated by TGFβ in human HEMC cells 
and was also elevated in human breast cancer. We have decided to refer to the human 
lncRNA as TIL, because this is TGFβ Induced LncRNA. TIL was of particular interest 
given its proximity to the C-MYC gene (e.g., residing ~10MB upstream of C-MYC) in 
8q23-24 region. Recently, several reports have suggested that locally residing lncRNAs 
can regulate C-MYC expression by various mechanisms [61, 86, 87]. Therefore this led 
to the hypothesis that TIL may also regulate C-MYC expression. 
 Knockdown and over-expression studies demonstrated that TIL regulated C-
MYC protein expression, however, had no effect on C-MYC mRNA levels. These results 
suggest TIL regulation of C-MYC at post-transcriptional level. We identified NF90 as a 
binding partner for TIL.  NF90 is a dsRBP capable of regulating target gene expression 
through interaction with AU-rich elements (AREs) within the 3-prime UTR [193].  We 
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next found that C-MYC messenger contains 4 AREs and also physically associates with 
NF90, and this interaction likely stabilizes the mRNA. Furthermore, it has been reported 
that AKT phosphorylation of NF90 at Ser647 is critical for NF90 shuttling from nuclear to 
cytosol [194]. We have shown that TIL enhances phospho-NF90 level and promotes 
NF90 export from the nucleus. Taken together, we hypothesize that TIL enhances 
nuclear export of NF90 which increases C-MYC mRNA stability in cytosol and C-MYC 
protein product. This chapter aims to discuss these mechanisms in further detail. 
 
Results 
  
TGFβ-regulated AK060 and human ortholog TIL. AK060 is a mouse lncRNA 
predicted to have a human ortholog. In “BLAST-ing” mouse AK060 to the human 
genome, we observed significant sequence conservation at intergenic region on 
chromosome 8. AK060 is conserved across several species to varying degrees, and in 
human exhibits 88% identity across 44% coverage (Figure 36A). 
This result was interesting to us given the close proximity to the C-MYC gene 
locus (~10MB; Figure 36B). There have been previous reports of lncRNAs residing 
within this genomic region that regulate C-MYC [61, 86, 195]. Next we validated 
regulation by TGFβ of AK060 and human ortholog in NMuMG and HMEC cell lines, 
respectively (Figure 36C and 36D). In human, this conserved transcript is induced 
greater than 3-fold in response to 24 hours TGFβ treatment versus vehicle control. We 
thus named the human transcript TIL (TGFβ Induced LncRNA). 
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Figure 36. AK060/TIL is a conserved TGFβ-upregulated lncRNA. (A) “BLAST” 
analysis of mouse AK060 transcript showed significant sequence identity and coverage 
at syntenic loci 8q23 in human. (B) Diagram shows that TIL is ~10 MB away from C-
MYC. (C) NMuMG and (D) HMEC were treated with TGFβ (5ng/ml) for 24 hours and 
expression of AK060 and TIL were measured by RT-qPCR. 
 
 
 TIL is elevated in human breast cancer and associates with late stage 
tumor and triple-negative breast cancer. We next evaluated TIL expression in a 
panel of human breast cancer cell lines. In comparison to HMEC normal cell, several 
cancer lines show significant over-expression of TIL, notably HS578T, MDA-MB-231, 
SKBR3, and CAMA1 (Figure 37A). Furthermore, we obtained 16 normal and 32 primary 
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breast tumor RNAs from H. Lee Moffitt Tissue Core. In the normal breast, semi-qPCR 
showed almost no expression of TIL. However, TIL is frequently overexpressed in tumor 
RNA samples (Figure 37B). Furthermore, we also obtained 8 pairs of adjacent normal 
and breast tumor RNAs. In 6 of the 8 pairs we observed overexpression of TIL (Figure 
37C). 
 
 
Figure 37. TIL is elevated in breast cancer cell lines and primary tumors. (A) Semi-
qPCR for TIL expression was performed in a panel of e breast cancer cell lines. (B and 
C) Indicated normal and breast tumors were subjected into semi-qPCR analysis for 
expression of TIL. 
  
 Next, we performed in situ hybridization analysis on breast TMAs which contain 
cores of normal epithelia, DCIS, IDC, and lymph node metastasis. A pattern emerged in 
that TIL was shown to have progressively higher expression as disease became more 
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advanced. For example, expression in DCIS was higher than normal, and expression in 
IDC was higher than DCIS. The most significant overexpression was observed in the 
metastasis (Figure 38A). Representative images were taken for cores in each group 
(Figure 38B). Based on the data available, we assessed if there was any significant 
association between elevated TIL and patient clinical and pathological characteristics. 
Our analysis revealed that high expression of TIL correlates with late stage tumor, 
positive lymph node metastasis, and triple-negative breast cancer (Figure 38C). There 
was however no significant correlation with overall survival as shown by Kaplan-Meier 
Plot (Figure 38D). This result may be due to a non-stratified population and the limited 
number of breast cancer examined. For example, if we were to separate the population 
into late-stage versus early-stage, or triple-negative versus ER-positive populations, we 
may see significant survival data. In this study, however, there are very few patients 
with late-stage and triple-negative breast cancer to make this conclusion (data not 
shown). The prognostic value of TIL warrants further investigation. 
  
TIL regulates migration, invasion, and has elevated expression in BCSCs. 
Expression of TIL is high in the triple-negative and highly invasive MDA-MB-231 breast 
cancer cell line. Therefore, we used this cell line to confirm knockdown of TIL 
expression using 2 siRNAs (si-TIL-1 and si-TIL-2) compared to si-CTL (Figure 39A). 
Once knockdown was confirmed, we assayed MDA-MB-231 for phenotypic changes in 
migration and invasion. After 48 hours of TIL depletion, cells for each group were 
seeded in upper chambers and assayed for migration and invasion. After 16 h, top 
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Figure 38. TIL is progressively up-regulated with advanced disease and 
associates with late stage tumor, positive lymph node, and triple-negative breast 
cancer. (A) TMA-ISH was performed using LNA-probe and scored. (B) Representative 
images of patients in each group are shown. (C) Correlation of clinical and pathological 
data with TIL expression. (D) Kaplan-Meier curve representing overall survival. 
 
 
chambers were cleared and number of migratory cells were quantified by 4 non-biased 
fields. Loss of TIL resulted in significant reduction of both migration and invasion in 
comparison to control (Figure 39B and 39C). 
 Next, a cDNA clone of TIL was generated using SKBR3 RNA as a template. 
Primers were designed based on the large human exon conserved in human from 
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mouse AK060. We called this region “Exon 3” and hypothesized this to contain 
functional domain. As predicted we amplified a 657nt insert in which we cloned into the 
pcDNA3.1+ expression vector. Next, we over-expressed TIL in MCF7 cells (Figure 39D). 
Ectopic introduction was able to induce invasion capacity >3-fold compared to vector 
control (Figure 39E). 
 To address if TIL is involved in regulation of breast cancer stem cell (BCSC) 
property, we treated the HMEC cells with TGFβ (5 ng/ml) for 9 days. HMEC cells 
underwent EMT in about 24 hours, and beyond this continually moved towards a stem-
like status. Using this method, it is possible to generate a significant population of 
CD44+/CD24- cells in culture, indicative of BCSC population. Next, the cells were 
sorted by flow for CD44-/CD24+ and CD44+/CD24- populations and RNA was isolated. 
RT-qPCR analysis showed that there was ~13-fold higher expression of TIL in the 
BCSC population compared to non-BCSCs (Figure 39F). 
 
TIL post-transcriptionally upregulates C-MYC. TIL locates at chromosome 
8q23, about 10MB away from C-MYC gene. Due to close proximity, and ability of 
lncRNAs to target neighboring gene expression in “cis”, we directly addressed whether 
TIL regulates C-MYC. We first silenced TIL expression in MDA-MB-231 cell using si-
TIL-1 (Figure 40A). As shown in Figure 39A, this siRNA gives ~80% knockdown. Next, 
we checked whether loss of TIL expression resulted in changes in C-MYC mRNA or 
protein levels. Interestingly, we observed no change in C-MYC mRNA after TIL 
knockdown, however we did detect significant drop in C-MYC protein expression 
(Figure 40B and 40C). Furthermore, we introduced TIL into MCF7 cells and found that 
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ectopic expression of TIL also had no effect on C-MYC mRNA, but dramatically induced 
total C-MYC protein levels (Figure 40D-F). 
 
 
Figure 39. TIL regulates migration, invasion, and has higher expression in BCSCs. 
(A) MDA-MB-231 cells were transfected with si-CTL, si-TIL-1, and si-TIL-2 for 48 hours 
and semi-qPCR was performed. (B and C) After 48 hours transfection, cells were 
seeded in upper chamber for 16 h and assayed for migration (B) and invasion(C). (D) 
pcDNA-TIL was transfected into MCF7 and measured by semi-qPCR.  (E) After 48 
hours transfection, MCF7 cells were seeded in upper chamber and assayed for invasion. 
(F) HMEC cells were treated with TGFβ for 9 days and sorted by flow for CD44-/CD24+ 
and CD44+/CD24- populations. RNA was isolated and examined for TIL expression by 
RT-qPCR. Asterisks represent p<0.05. 
 
 
It has also been well documented that in normal breast and early onset of breast 
cancer, TGFβ treatment will result in down-regulation of C-MYC mRNA and protein 
expression [196]. In this case such as in HMEC, TGFβ pathway will act as a tumor 
suppressor. However, in breast cancers where the “switch” has occurred, TGFβ 
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treatment will induce C-MYC mRNA and eventual protein expression to trigger 
oncogenic phenotypes. This is the case with MDA-MB-231 line, in which 24 h TGFβ 
treatment (5ng/ml) induced C-MYC mRNA ~3-fold (Figure 40G). MDA-MB-231 cells 
were transfected with si-CTL and si-TIL for 48 hours and left untreated or treated with 
TGFβ for 24 hours. In the absence of TIL, TGFβ-induced C-MYC mRNA levels remain 
unaffected after 24 hours (Figure 40G). Interestingly, C-MYC protein expression is 
dramatically inhibited as shown by time course of TGFβ treatment (Figure 40H). This 
result suggests that TIL post-transcriptionally regulates C-MYC expression. 
 
TIL binds to NF90. To elucidate the mechanism by which TIL post-
transcriptionally regulates C-MYC, we aimed to identify a protein binding partner. To do 
this we used the non-biased RIP assay described in Chapter 4.  Briefly, in vitro 
transcribed biotinylated “Sense” and “Antisense” TIL RNAs were incubated with 1mg 
MDA-MB-231 protein extract. RNA-protein complexes were immunoprecipitated using. 
Streptavidin-agarose, washed, boiled, and run on SDS-page gel. We observed a 
very strong unique band at ~90 kDa in the “Sense” lane that was not visible in the 
“Antisense” lane (Figure 41A). This band was excised and subjected to mass 
spectrometry protein identification. The data suggested a strong enrichment for the 
NF90 protein in “Sense” versus “Antisense” samples. To further investigate the 
interaction of TIL with NF90, we performed similar RIP experiment as described above 
with minimal modification. After running SDS-page gel, total bound proteins were 
transferred to nitrocellulose membrane.  Western blotting analysis was carried out with 
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an antibody against NF90. We observed significant expression of NF90 in “sense” lane 
and virtually no expression in the “antisense” lane (Figure 41B). 
 
 
 
Figure 40. TIL regulates C-MYC at protein but not mRNA level. (A) MDA-MB-231 
cells were transfected with si-CTL and si-TIL-1 and subsequently subjected into real-
time PCR analysis of TIL expression. (B and C) After 48 hours of knockdown of TIL, C-
MYC mRNA and protein expression was measured by RT-qPCR (B) and Western blot 
analysis (C). (D - F) MCF7 cells were transfected with pcDNA-TIL and vector control. 
Following 48 hours of incubation, RT-qPCR was performed to examine the expression 
of transfected plasmids (D) and C–MYC mRNA (E).  C-MYC protein levels were 
assessed by western blotting (F). (G) MDA-MB-231 cells were transfected with si-CTL 
and si-TIL-1 for 48 h. Samples were left untreated or treated with TGFβ (5 ng/ml) for 24 
hours. Total RNA was isolated and expression of TIL and C-MYC mRNA was assessed 
by RT-qPCR. (H) Cells were similarly transfected as described in panel G.  Following 
treatment with TGFβ for indicated time, immunoblot analysis was performed with anti-C-
MYC antibody. GAPDH was used as a loading control. 
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 Next, we performed the reverse experiment to see if NF90 bound endogenous 
TIL in vivo. To do this, we lysed MDA-MB-231 cells, and then incubated with anti-GFP 
or anti-NF90 antibodies. Immunoprecipitation was performed using protein A/G beads 
and total bound protein-RNA complexes were resuspended in Trizol buffer. Total RNA 
was then isolated and semi-qPCR was performed. We observed a significant 
enrichment of endogenous TIL in the anti-NF90 samples as compared to anti-GFP 
(Figure 41C). These results suggest that endogenous NF90 binds to endogenous TIL in 
vivo. 
 
C-MYC binds to NF90. Since TIL induces C-MYC protein level and binds to 
NF90, we next investigated if NF90 mediates TIL effect on C-MYC. NF90 is known to 
bind AU-rich elements (AREs) within the 3’UTR of mRNAs to influence target gene 
expression. NF90 can be bi-faced and multifunctional in that it can promote mRNA 
stability and degradation, as well as facilitate nuclear export of transcripts to the cytosol 
[197, 198]. We therefore analyzed the 3’UTR of C-MYC for presence of AREs using 
“AREsite” software [199] and found four distinct AUUUA motifs within 3’UTR of C-MYC 
(Figure 42A). 
Furthermore, we cloned C-MYC 3’UTR (e.g., 474nt) into pcDNA3 vector for in 
vitro transcription. Next, we generated biotinylated “sense” and “antisense” RNA probes 
and performed similar RIP experiment with MDA-MB-231 extract as described above to 
assess whether the 3’UTR of C-MYC binds to NF90. Indeed, after isolating RNA-protein 
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Figure 41. TIL binds to NF90. (A) RIP was performed by incubation of 3ug biotinylated 
“sense” and “antisense” RNAs of TIL with 1mg MDA-MB-231 extract in the presence of, 
Streptavidin-agarose. Following wash, total bound protein was run on SDS-page gel 
and silver stained. Unique bands were subjected to protein identification by mass 
spectrometry. (B) Similar RIP was performed and total bound protein was transferred to 
nitrocellulose for Western blot analysis with NF90 antibody. (C) Immunoprecipitates 
were prepared with antibodies against GFP and NF90 and then were used to isolate 
RNA.   Endogenous TIL expression was evaluated with semi-qPCR. 
 
complexes by Streptavidin-agarose, Western blot analysis showed a strong enrichment 
for NF90 in “sense” but not “antisense” (Figure 42B). Next, we performed IP on 
endogenous NF90 and confirmed interaction with C-MYC mRNA transcript in vivo by 
semi-qPCR (Figure 42C). Taken together, these data suggest that the C-MYC 3’UTR 
contains AREs which interact with NF90. 
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TGFβ  induces TIL-dependent shuttling NF90/C-MYC to cytosol. We next 
investigated the significance of TGFβ stimulation in relation to the TIL/NF90/C-MYC 
interaction. Since NF90 can stabilize transcripts in the cytosol to enhance protein 
expression and since NF90 binds to C-MYC mRNA, We hypothesized that TGFβ and 
TIL may facilitate this process. First, we treated the MDA-MB-231 with TGFβ to examine 
for change of NF90 localization. Indeed, TGFβ significantly induced shuttling of NF90 
from nuclear to cytosol following the treatment for 24 hours (Figure 43A). However, if 
cells are first depleted TIL using siRNA, NF90 shuttling in response to 24 hours TGFβ 
treatment is almost completely abolished (Figure 43B). In the low-TIL expressing BT474 
cell line, ectopic expression of TIL can enforce NF90 shuttling from nuclear to cytosol, 
however has no effect on total NF90 protein levels (Figure 43C). This result suggests 
that TIL/NF90 interaction is important for NF90 shuttling from nuclear to cytosol. 
Since C-MYC mRNA also binds to NF90, we tested whether TIL can also drive 
C-MYC mRNA to cytosol. We ectopically expressed TIL in BT474 and observed that TIL 
promoted C-MYC mRNA from nuclear to cytosol. Presumably this shuttling is through 
C-MYC mRNA being bound to NF90 (Figure 43D). We have shown that ectopic TIL 
results in increased C-MYC protein, likely the result of increased C-MYC mRNA. To 
further demonstrate that ectopic TIL increase of C-MYC protein is through C-MYC 
3’UTR interaction with NF90, we cloned the 3’UTR of C-MYC into luciferase reporter 
construct (pMIR-Luciferase-3’-UTR-C-MYC). Cells were first transfected with reporter 
alone or 3’UTR containing reporter.  After 24 hours, cells were co-transfected with 
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Figure 42. NF90 binds to C-MYC 3’UTR. (A) AREsite software identified four AUUUA 
motifs within the 3’UTR of C-MYC. (B) Three microgram biotinylated “sense” and 
“antisense” C-MYC 3’UTR RNA probes were incubated with 1mg MDA-MB-231 extract. 
Western blotting was performed for NF90 interaction with 3’UTR of C-MYC. (C) Anti-
GFP and anti-NF90 were incubated with MDA-MB-231 extract and then 
immunoprecipitated in the presence of protein A/G. Total RNA was isolated and semi-
qPCR was performed for C-MYC mRNA. 
 
pcDNA or pcDNA-TIL. In cells co-transfected with 3’UTR containing reporter and TIL 
(V2+TIL), bioluminescence activity was significantly increased compared to controls. 
(Figure 43E). Taken together, these results suggest that TIL forces C-MYC mRNA to 
the cytosol, and this shuttling is dependent on the 3’UTR of C-MYC. 
  
TIL enhances AKT phosphorylation of NF90 at Ser647. A previous report has 
demonstrated that phosphorylation of NF90 at Ser647 by AKT is essential for NF90 
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shuttling out of the nucleus to cytosol for binding and stabilization of IL-2 [194, 198]. We 
therefore hypothesized that TIL may be involved in this phosphorylation event. To test 
this, we transfected MCF7 with vector and TIL, and then NF90 was immunoprecipitated. 
Since no antibody exists for NF90-p-Ser647, we probed the Western blot using 
 
 
Figure 43. TGFβ enhances TIL-dependent NF90 and C-MYC mRNA shuttling to 
cytosol. (A) MDA-MB-231 cells were treated with TGFβ (5 ng/ml) and cells were 
fractioned to check for localization of NF90. (B) Cells were transfected with si-CTL or si-
TIL for 48 hours and then treated with TGFβ for 24 hours. Cells were fractioned for 
Western blot analysis with NF90 antibody. (C and D) BT474 cells were transfected with 
ectopic TIL and fractioned for Western blot for NF90 (C) and RT-qPCR for C-MYC 
mRNA (D). (E) HEK293 cells were transfected with V1 (pMIR-Luciferase) or V2 (pMIR-
Luciferase-3’UTR-C-MYC) for 24 hours. Cells were co-transfected with pcDNA or 
pcDNA-TIL for 48 hours. At total 72 hours time point, cells were lysed and luciferase 
activity was measured. 
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phospho-AKT-substrate antibody, which recognizes the RXRXXS/T motif of typical AKT 
phosphorylation. We observed a significant increase in signal in cells transfected with 
TIL at band consistent with size NF90. However, after stripping and reprobing the blot 
we observed no change in total NF90 levels (Figure 44A). It is important to note that 
Ser647 is the only residue of NF90 being phosphorylated by AKT. Therefore any signal 
observed using phospho-AKT-substrate antibody is indicative of p-Ser647. The same 
result was observed by co-transfecting NF90-GFP with TIL (Figure 44B). 
We further determine if loss of TIL results in a drop in p-Ser647 signal. Previously 
it has been shown that TGFβ-induced EMT in mammary epithelia is through 
downstream signaling of the AKT pathway. This report demonstrated that TGFβ 
treatment coincided with activation of p-SMAD3/1 and p-AKT-473 [200]. Therefore, we 
knocked down TIL for 48 hours in MDA-MB-231, and then treated cells for 30 minutes 
with TGFβ to check for changes in p-Ser-647 of NF90. We observed a substantial 
increase of p-Ser647 in si-CTL transfected cells treated TGFβ compared to untreated, 
as predicted. However, if TIL was depleted prior to TGFβ treatment, NF90 p-Ser647 
levels were completely lost to levels even below untreated cells (Figure 44C). These 
results suggest that TIL is involved in enhancing the phosphorylation of NF90 at Ser647 
by AKT. 
 
Discussion 
  
We propose a model by which TIL regulates C-MYC expression through the 
RNA-binding protein NF90 (Figure 45). TIL and C-MYC locate ~10MB apart in the 8q23-
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24 locus, a region of the genome that has been implicated in several cancers. Elevated 
expression of C-MYC has also been reported to be a driver in several malignancies 
including breast cancer. We have demonstrated that TGFβ induces TIL and C-MYC 
expression at RNA level. We have referred to this arm of TIL-pathway as the 
“transcriptional” pathway, and likely TIL and C-MYC are together up-regulated by 
canonical TGFβ signaling and SMAD-dependent target gene expression. Therefore 
TGFβ treatment will result in elevated levels of both TIL and C-MYC. 
 
 
 
 
Figure 44. TIL promotes phosphorylation of NF90 at Ser-647. (A) MCF7 cells were 
transfected with vector or TIL for 48 hours. NF90 was immunoprecipitated and the 
immunoprecipitates were then immunoblotted with AKT-substrate antibody. (B) MCF7 
cells were co-transfected with NF90-GFP and either vector or TIL for 48 h. 
Immunoprecipitation was performed using anti-GFP and then immunobloted with AKT-
substrate antibody. (C) MDA-MB-231 cells were transfected with si-CTL or si-TIL for 48 
hours. Cells were then treated with TGFβ (5 ng/ml) for 30 m. Immunoprecipitation and 
Western blot were done as described in panel A. 
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The second arm of the pathway we have referred to as the “translational”, named 
such since it acts to regulate C-MYC post-transcriptionally. This pathway requires TGFβ 
activation of AKT, a known regulator in translational process. We have shown that TIL 
binds to NF90, and that this binding is critical for enhancing AKT phosphorylation at 
Ser647. This phosphorylation site is the critical event which triggers NF90 translocation 
to the cytosol. In the absence of TIL, NF90 phosphorylation and shuttling from nucleus 
to cytosol are dramatically inhibited. Enforced expression of TIL can increase p-NF90-
Ser647 and shuttling NF90 to cytosol. Once in the cytosol, NF90 also binds to AREs of 
C-MYC-3’UTR, which promotes C-MYC mRNA stability and increases C-MYC 
translation. 
A major question remains as to how TIL enhances phosphorylation of NF90. One 
explanation is that TIL binds to NF90 first, and this binding results in protein 
conformational change to open up Ser647 availability for AKT. Another possibility is that 
AKT phosphorylation happens first, and this site is stabilized and protected from 
phosphatase activity subsequently by TIL binding. Yet a third possible scenario is that 
TIL acts as a molecular scaffold that can also bind to AKT, and serve to direct the 
successful interaction between the two proteins. The C-MYC mRNA also serves as a 
player in this complex, and similar questions remain as to the order of events of TIL and 
C-MYC mRNA binding to NF90. NF90 contains 2 RBDs, so it is possible that TIL and C- 
MYC mRNA binding occurs independently, or lncRNA or mRNA bind first to induce a 
protein conformational change to load the second RNA product. The axis by which 
TIL/C-MYC/AKT/NF90 work together is a very dynamic process, and one that warrants 
future investigation. 
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Figure 45. A model proposed by which TIL regulates C-MYC through NF90. TGFβ 
can activate target gene transcription through SMAD signaling. TIL and C-MYC are both 
transcriptionally activated. TGFβ can also activate the AKT pathway which can influence 
translation regulatory machinery in the cell. TIL binding to NF90 enhances AKT 
phosphorylation of NF90-Ser647 and C-MYC mRNA shuttling to the cytosol. Once in 
the cytosol, NF90 can bind to ARE-containing elements in the 3’UTR of C-MYC to 
stabilize transcript and increase protein expression. 
 
Methods 
 
RNA immunoprecipitation (RIP) assay. Briefly, 3ug biotinylated Sense and 
Antisense in vitro transcribed TIL was incubated with 1mg HEK293 extract in RIP Buffer, 
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respectively. Ribonucleoprotein complexes were immunoprecipitated using Streptavidin-
agarose (Life Technologies). IPs were washed in RIP Buffer and total isolated protein 
was run on SDS-PAGE gel and silver stained. Unique bands were submitted for Mass 
Spectrometry protein identification. Previously described in Chapter 4. 
 
Locked nucleic acid in situ hybridization of formalin-fixed, paraffin-
embedded tissue microarray (LNA-TMA-ISH). TIL LNA probe was end labeled with 
digoxigenin-ddUTP terminal transferase. After deparaffinization and antigen retrieval, 
hybridizaton with 10 nmol/L LNA TIL probe for 12 hours. After washing sections were 
blocked for 1 h and incubated with anti-DIG-AP Fab. Following washing TMAs were 
processed and then visualized. 
 
Immunofluorescence,  immunoblotting, and antibodies. As described in 
Chapters 3 and 4. Antibodies against total C-MYC was from Santa Cruz 
Biotechnologies (Santa Cruz, CA, USA), NF90 from Bethyl Laboratories (Montgomery, 
TX USA), phospho-AKT substrate (RXXS/T) from Cell Signaling Technologies (Danvers, 
MA USA). 
 
Plasmids and siRNAs. A 656nt cDNA insert of TIL (Exon3) was amplified and 
TA-cloned into pGEM-T-easy vector Plasmid containing insert was sequenced, insert 
was then isolated by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-TIL). 
C-MYC 3-prime UTR cDNA was amplified using Green Taq PCR Master Mix (Promega) 
and cloned into pMIR-REPORT luciferase reporter vector (Life Technologies). SiRNAs 
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were designed using IDT siRNA Design Software. Two best siRNAs against human TIL 
were determined empirically and used for experimentation.  
 
BCSCs sorting by flow for RT-qPCR. HMEC cells were treated with TGFβ (5 
ng/ml) for 9 days. Cells were then washed in PBS, trypsinzed, and incubated with 
antibodies for CD24-FITC and CD44-PE from BD Biosciences (San Jose, CA USA). 
Cells were then sorted by flow cytometry for FITC-positive cells, indicative of 
CD24+/CD44- population, and PE-positive cells indicative of CD44+/CD24- population. 
Total RNA was isolated from both populations via Trizol and TIL expression was 
evaluated by RT-qPCR. 
 
Dual reporter luciferase assay. HEK293 cells were transfected with pMIR-
Luciferase (firefly) containing constructs and renilla luciferase control plasmid were co-
transfected. After 24 hours, pcDNA or TIL was then transfected for 48 hours. At 72 
hours time point, cells were lysed, and signal for firefly and renilla luciferase was 
measured using Dual-Luciferase Reporter Assay System from Promega. Results are 
representative of triplicate ratios firefly/renilla luciferase signals.
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CHAPTER 6: 
Conclusions and Implications 
 
 Accumulating evidence indicates that the majority of the mouse and human 
genomes are transcribed into ncRNAs. Several classes of functional ncRNAs are 
emerging within the cell, including lncRNAs. The functional contribution of lncRNAs to 
tumorigenesis and cancer progression remains elusive. 
 The central focus of this dissertation work is to characterize the biological 
mechanisms of lncRNAs in the context TGFβ-mediated phenotypes in metastatic breast 
cancer, such as EMT and cancer cell stemness. In the initial stages, the primary mouse 
mammary cell line NMuMG was treated with TGFβ to induce EMT. Global changes in 
lncRNA gene expression were profiled by microarray and significant changes were 
validated by RT-qPCR. Our analysis revealed that a total of ~600 lncRNAs were 
induced or repressed in this response, respectively. LncRNAs are poorly conserved 
across species, however there are examples of well conserved lncRNAs that function in 
cancer [33, 48]. Therefore, we developed a strategy to predict mouse lncRNAs that had 
a strong potential for a human ortholog. 
The motivation behind this strategy was that the end goal was to characterize 
important lncRNAs in human cancer. Also, proteins are prime examples of genomic 
regions that are very well conserved and contain function gene products. If lncRNAs 
  
 125 
demonstrated similar features, it was likely that this evolutionary selection was due to 
the fact that a functional gene product resided in this genomic location. Therefore, our 
hypothesis suggested that ortholog lncRNAs are more likely to be functional due to 
selective evolutionary pressures.  Strategically, conserved lncRNAs will allow us to 
carry out knockout and transgenic animal studies in order to define physiological and 
pathological function of these lncRNAs in vivo. 
The strategy to predict mouse lncRNAs with a strong potential for a human 
ortholog took into account 4 parameters; significant sequence identity and coverage of 
transcript, identity mapped to syntenic loci in both genomes, regulated by established 
transcriptional factor and pathway (TGFβ), and corresponding transcripts were 
intergenic and free standing. Next, we subjected the top 100 mouse lncRNAs induced 
by TGFβ in the microarray analysis to these parameters. Ten mouse lncRNAs emerged 
as potentially having a human ortholog. Follow-up experimentation showed that 9 were 
detected at the RNA level in human (denoting ortholog transcript), 3 were also under 
regulation of TGFβ in human, and 1 resided in a genomic location of interest. 
  This study focused on characterizing 3 of conserved lncRNAs; lncRNA-HIT, 
WDFY3-AS2, and TIL. LncRNA-HIT is a 5-prime distal Hoxa residing transcript. It is 
becoming well established that Hox gene clusters are lncRNA-governed, and several 
important examples have surfaced in literature detailing this regulation [149, 150]. 
Knockdown experiments using siRNA showed that mouse lncRNA-Hit is functional in 
driving TGFβ-induced EMT, migration, and invasion. Overexpression of lncRNA-Hit 
disrupted tight junction in NMuMG and this correlated with a drop in E-cadherin 
expression. Furthermore, human lncRNA-HIT is significantly elevated in breast cancer, 
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and this elevated expression associates with invasive disease, high grade tumor, and 
metastatic breast cancer (i.e., lymph node metastasis). LncRNA-HIT positively regulates 
HOXA13 mRNA and protein expression in human cell lines. Elevated expression of 
lncRNA-HIT could drive high levels HOXA13 in patient tumor to drive oncogenic and 
metastatic processes. 
 WDFY3-AS2 lies in the antisense orientation to protein coding gene WDFY3 on 
chromosome 4q21, and also drives TGFβ-mediated phenotypes such as cell motility 
and EMT. High levels of WDFY3-AS2 in patients are associated with late stage tumor, 
triple-negative subtype, and poorer overall patient survival. Our experimentation has 
shown that WDFY3-AS2 positively regulates WDFY3 and STAT3 through protein 
binding partner hnRNPR. WDFY3 is a critical regulator of selective macroautophagy by 
serving as an adapter for recruitment of the core autophagic machinery. Interestingly, it 
has been suggested that several triple-negative breast cancers are driven by STAT3 
addicted autophagy. WDFY3-AS2 could be a bridge to link these 2 molecules in TGFβ-
induced autophagy potentiating a signaling loop that drives cancer phenotypes. 
 TGFβ-regulated TIL is an 8q23-24 residing lncRNA that also promotes EMT and 
cancer cell stemness. In breast cancer patients, elevated levels of TIL associate with 
late stage tumor, metastasis, and triple-negative subtype. There have been several 
examples of functional lncRNAs in the 8q23-24 region that can regulate C-MYC 
expression. Therefore, we examined if TIL also has similar function toward C-MYC. Our 
experiments demonstrated that TIL can post-transcriptionally regulate C-MYC through 
NF90. Interestingly, TIL enhances phosphorylation of NF90 by AKT resulting in 
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increased shuttling of NF90 to the cytosol. In cytosol, NF90 can bind to and stabilize C-
MYC mRNA and increase C-MYC protein expression. 
 The 3 candidates mechanistically function very differently from each other 
illustrating the dynamic roles of lncRNA can play within a cell. Clearly disruption and 
deregulation of lncRNA expression can be important in driving tumorigenesis and 
metastatic processes.  
The translational impact of lncRNAs is an emerging aspect that has yet to be 
extensively explored. In future, there is a great potential for using lncRNA as biomarkers 
for diagnostics, monitoring recurrence, and predicting response to therapy.  A major 
advantage of using RNA as tool and readout is the fact that it can be detected using 
PCR based technologies. This means that only a small amount of material is needed to 
be informative, and this material can be acquired through non-invasive means like blood 
and urine. If a panel of lncRNAs could be identified as specific to a particular cancer, 
this could provide a novel avenue to non-invasive preventative screening and diagnosis. 
This same principle could be applied to monitoring tumor recurrence and metastasis 
after surgery and chemotherapy. 
LncRNAs could also serve as important biomarkers in personalized and precision 
medicine. For example, it has been reported that triple-negative breast cancers driven 
by STAT3-addicted autophagy are responsive to drugs like chloroquine and bafilomycin. 
In this case, the status of WDFY3-AS2 expression in the primary tumor would be a 
powerful readout for prediction and repurposing these FDA approved drugs. Similarly, 
TIL can be a marker of MYC driven malignancy and these patients could be benefit from 
newer drugs like JQ-1. 
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Of course with the identification of novel oncogenic drivers of cancer, the 
question is always asked if these molecules can serve as direct targets for therapy. 
There is a major research effort underway to begin targeting the “un-druggable”, which 
currently includes the nucleic acids and proteins like transcription factors. This is an 
exciting time to expand the therapeutic toolbox, however I do believe directly targeting 
lncRNAs in cancer may still take a lot of efforts to prove efficacious. Traditionally, 
delivering nucleic acid based therapies, like small antisense oligos (ASOs), has been 
difficult due to limitations in methods of delivery and stability of the molecules once 
systemically administered. In principle, however, drugs designed against RNAs could be 
more specific than those against protein given the exactness of Watson-Crick base 
pairing.  Future extensive investigation is required for better understanding the basic 
underlying biology of lncRNAs and their role in human malignancy such as metastatic 
breast cancer with aiming to develop biomarkers and effective novel targeted therapy.  
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